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ABSTRACT 
The production of extracellular vesicles (EV) is a ubiquitous feature of eukaryotic cells but pathological 
events can affect their formation and constituents. We sought to characterize the nature, profile and 
protein signature of EV in the plasma of Parkinson’s disease (PD) patients and how they correlate to 
clinical measures of the disease. EVs were initially collected from cohorts of PD (n=60; Controls, n=37) 
and Huntington’s disease (HD) patients (Pre-manifest, n=11; manifest, n=52; Controls, n=55) – for 
comparative purposes in patients with another chronic neurodegenerative condition – and exhaustively 
analyzed using flow cytometry, electron microscopy and proteomics. We then collected 42 samples from 
an additional independent cohort of PD patients to confirm our initial results. Through a series of 
iterative steps, we optimized an approach for defining the EV signature in PD. We found that the number 
of EV derived specifically from erythrocytes segregated with UPDRS scores corresponding to different 
disease stages. Proteomic analysis further revealed that there is a specific signature of proteins that 
could reliably differentiate control subjects from mild and moderate PD patients. Taken together, we 
have developed an EV blood-based assay that has the potential to be used as a biomarker for PD.
Key words: Blood cells; Erythrocytes; Extracellular vesicles; Alpha-synuclein
HIGHLIGHTS:
 Optimization of methodology to identify extracellular vesicles (EV) using FACS
 Demonstration of minimal test-retest variability intra-patient using FACS
 Development of a new approach to uncover the entire proteome of EV
 Segregation of Parkinson’s disease patients with EV from erythrocytes (EEV) count
 EEV protein signature differentiates control from Parkinson’s disease patients
ABREVATIONS 
EV: Extracellular vesicles,
EEV: Extracellular vesicles derived from erythrocytes
LEDD: levodopa equivalent daily dose
UPDRS: Unified Parkinson Disease Rating Scale
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INTRODUCTION 
The last few years of research has seen our understanding of Parkinson’s disease (PD) change 
dramatically. One of the major breakthroughs has been the realization that PD is a heterogeneous 
disorder, which brings with it challenges for the development and identification of useful biomarkers for 
diagnosis and disease progression, as well as the ability to track the successful translation of novel 
treatments to the clinic. This new understanding of the different clinical profiles seen in populations of 
PD patients has begun to translate into a redefinition of PD, as is evidenced by new diagnostic criteria 
released by the International PD and Movement Disorder Society (MDS) (Berg et al., 2014). This task 
force has also pointed out the importance of identifying reliable biomarkers for clinico-pathological 
diagnoses. Indeed, the development of a biomarker that could serve as a diagnostic tool, and/or a 
dependable predictor of disease course and evolution (and thus stratify populations of patients) as well 
as to assess treatment efficacy is of critical importance and urgently needed.
The search for such biomarkers has recently included the investigation of extracellular vesicles (EV); 
small entities that carry critical intracellular molecules and which mediate cell-to-cell communication in 
both physiological and disease conditions (Quek and Hill, 2017). EV are composed of membrane proteins 
and lipids, as well as cytoplasmic components of the cell from which they originate, such as mRNA and 
miRNA, organelles or infectious particles (e.g. prions, virus) (Porro et al., 2015). Their protein cargo, cell 
signature and availability in bodily fluids make EV very attractive candidate biomarkers and have already 
been studied in the blood, cerebrospinal fluid (CSF), urine and brains of patients with PD (see Figure S1) 
(Abd-Elhadi et al., 2015; Alvarez-Erviti et al., 2011; Araki et al., 2016; Barbour et al., 2008; Bartels et al., 
2011; Danzer et al., 2012; El-Agnaf et al., 2006; Emmanouilidou et al., 2010; Fauvet et al., 2012; Fraser et 
al., 2013; Grey et al., 2015; Helferich et al., 2015; Ho et al., 2014; Kong et al., 2014; Kunadt et al., 2015; 
Melachroinou et al., 2013; Nakai et al., 2007; Nikam et al., 2009; Pretorius et al., 2014; Renella et al., 
2014; Shi et al., 2014; Stuendl et al., 2016; Sudha et al., 2003; Tomlinson et al., 2015; Tsunemi et al., 
2014; Wang et al., 2015). For example, EVs derived from the CSF contain α-synuclein (α-syn), its 
associated pathogenic species as well as the LRRK2 protein (Fraser et al., 2013). However, routinely 
collecting CSF presents a challenge given the invasive nature needed to collect it while plasma is a very 
accessible fluid that further allows real time monitoring, and which has consequently been more 
extensively studied from a biomarker perspective. 
One of the reasons that EVs have become attractive for biomarker development relates to advances in 
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their isolation involving ultracentrifugation, centrifugation by density gradient, size exclusion using 
membranes and columns, polymeric precipitation, capture by immune-affinity and microfluidic 
approaches (Shevchenko et al., 1996). However, the bulk of the already published work on EV in bio-
fluids relies on using a series of differential centrifugations with or without size filtration, for example 
gradient techniques that concentrate and purify EV (Konoshenko et al., 2018; Willis et al., 2017). 
Techniques utilizing solely the ultracentrifugation to perform EV counts are biased because they favor 
aggregations of vesicles while co-isolating a number of contaminants, such as proteins (Linares et al., 
2015). Techniques to isolate EV have therefore recently been developed with the goal of maintaining the 
integrity and purity of the isolated entities (Konoshenko et al., 2018). We sought to use these advances 
to develop new approaches that would allow for the optimal analysis of EV in blood, and therefore shed 
light on a more accurate picture of these elements in PD with the hope that this could be used for 
biomarker development. This work initially involved optimizing the FACS analysis by stringent controls to 
unequivocally identify EVs and their cell origin, performing test-retest experiments to validate 
consistency of results over time in the same patient and finally, using hemoglobin removal to uncover 
the entire proteome of EV analyzed. This having been done, we then sought to characterize the nature 
and profile of EV in the plasma of patients, and how they correlate to clinical measures of disease state 
as well as defining the protein content in the subpopulations of EV. Finally we sought to validate this 
whole approach using a second independent cohort of patients with PD.
MATERIALS AND METHODS
Ethics statement and participant recruitment
Institutional review boards approved this study (CHU de Québec, #A13-2-1096; CHUM, #14.228; 
Cambridge Central Regional Ethics Committee, REC #03/303 & #08/H0306/26; and Cambridge University 
Hospitals Foundation Trust Research and Development department, R&D #A085170 & #A091246) in 
accordance with the Declaration of Helsinki, and written informed consents were obtained from all 
participants. 
Blood samples were initially collected from 2 cohorts of patients with a total of 60 PD [one in Cambridge 
UK; one in Quebec Canada] as well as 37 age- and sex-matched healthy Controls (Table 1). For 
comparison, blood samples were also collected from a cohort of 52 Huntington’s disease (HD) individuals 
[collected in Montreal, Canada] along with 55 age- and sex-matched healthy Controls (Table S1). 
Subsequently, an additional and independent cohort of 42 PD patients was collected to corroborate the 
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results related to EEV counts obtained from these first cohorts of patients (Table S2). In the case of PD 
patients, the UK Parkinson’s Disease Society Brain diagnostic criteria were used, which gives a diagnostic 
accuracy of 98.6% when applied by movement disorder specialists (Hughes et al., 2002; Massano and 
Bhatia, 2012). The patients, at the time of bleeding, also underwent clinical evaluation which included 
the Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr (H&Y) scale, the Mini Mental State 
Examination (MMSE), the Addenbrooke's Cognitive Examination (ACE) and the Beck Depression 
Inventory (BDI). UPDRS was obtained from the UK and Montreal cohorts but not the Quebec cohort for 
logistical reasons. In the case of the HD patients, their Unified Huntington Disease Rating Scale (UHDRS), 
Total Functional capacity (TFC) and calculated values for burden of disease (BDS) were all collected at the 
time of venepuncture and their diagnosis was confirmed by genetic testing. Participants were further 
asked to fill out a questionnaire related to health issues and medication and a full blood count was 
performed in all patients on the day of blood sampling. Comorbidities were determined from medical 
information reported by the participant or caregiver. Cancer refers to a participant having suffered from 
any cancer in the past. Medications were converted into levodopa equivalent daily dose (LEDD) using 
common calculator tools. It should be noted that blood sampling was conducted by the exact same team 
of investigators, following identical procedures in both UK and Canada.
For the test-retest experiments, collection of blood samples was performed on 25 healthy individuals 
with 2 samples per subject, taken after a 2-hour interval. This cohort included 11 men and 14 women 
with a mean age of 29 ± 5 years with no clinical reports of co-morbidities or medication intake. Note that 
fasting was not required prior to blood samplings in any of the cohorts that were recruited for this study. 
Calculation of % CVs of concentration measurements of EEVs was performed using GraphPad PRISM® 
Version 6.0 (GraphPad Software, LaJolla, CA).
Preparation of platelet-free plasma and EV labeling
Citrated blood was centrifuged twice for 15 minutes at 2500g at room temperature. Platelet-free plasma 
(PFP) was harvested and stored at -80°C within 2 hours of sampling following previously published 
guidelines (Lacroix et al., 2012). For specific details on EV labeling, please refer to the supplementary 
material.
In all cases, the control samples came from healthy participants and the blood was collected at exactly 
the same time of day as for the PD and HD patients in the UK and Canadian clinics. Every blood sample 
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was processed immediately to avoid release of non-physiological EV. For analyses relating to EV in 
plasma, all blood samples were centrifuged twice at 2500g to enable PFP recovery. The plasma was 
fractionated into 3 aliquots per individual and frozen immediately following processing (maximum of 2 
hours following blood collection). Blood samples from Controls and PD were collected in parallel and 
laboratory analyses were blinded to participant status. 
Flow cytometry quantification
For EV quantification, we used a FACS Canto II Special Order Research Product equipped with a forward 
scatter (FSC) coupled to a photomultiplier tube (FSC-PMT) and a small particle option. Flow cytometer 
performance tracking was carried out daily using the BD cytometer setup and tracking beads (BD 
Biosciences, San Jose, CA, USA). The size of the EV was determined using fluorescent silica beads of 100, 
500 and 1000nm (Figure S2). The settings for the EV detection were determined as previously described  
using a threshold of 200 for SSC (also see Figure S2) (Rousseau et al., 2015). For specific details on 
plasma-related EV quantification, please refer to the supplementary material.
Production and purification of EEV
Blood was collected in heparin tubes and centrifuged for 10 minutes at 282g at room temperature. Blood 
cells were washed first in PBS-2%FBS, then with 0.9% sodium chloride solution and centrifuged for 10 
minutes at 750g. To avoid leukocyte and/or platelet contamination, the buffy coat and upper fraction of 
erythrocytes were removed. To preserve erythrocytes, two volumes of glycerolyte 57 solution (57% 
glycerol, 142mM sodium lactate, 1mM KCl, 25mM sodium phosphate pH 6.8) were added to the pellet 
and stored at -80°C. For the in vitro generation of EEV, red blood cells were thawed and EV production 
was induced as previously described (Minetti et al., 2004). For specific details on EEV purification, please 
refer to supplementary material.
C-reactive protein, free hemoglobin and -synuclein quantification
The concentrations of C-reactive protein (CRP) and free hemoglobin were determined in the PFP of all 
donors using the RayBio Human CRP ELISA Kit (RayBiotech, Norcross, GA, USA) and the Hemoglobin 
Human ELISA kit (Abcam, Toronto, ON, Canada). To quantify -syn within erythrocytes and EEV, we used 
the human -Syn ELISA kit (ThermoFisher Scientific, Waltham, MA, USA). Absorbance values were 
measured at 450nm using a multi-detection microplate reader (Synergy HT; BioTek; Winooski, VT, USA). 
All ELISA tests were performed according to the manufacturer's instructions.
Lamontagne-Proulx et al., 2018 
7
Scanning electron microscopy
For the visualization by scanning electron microscopy, EEV were prepared as previously described 
(Duchez et al., 2015). For specific details on EEV preparation, please refer to supplementary material.
Transmission electron microscopy
For transmission electron microscopy, EEV were prepared and observed as previously described (Duchez 
et al., 2015). For specific details on EEV preparation and labelling, please refer to supplementary 
material.
Mass spectrometry analysis and label free protein quantification 
The initial proteomic analyses were performed on 3 pools of 3 blood samples of each group. Following 
this, we undertook a completely new set of analyses to develop a method allowing us to isolate 
hemoglobin and better investigate the EEV proteome. For this, EVs from an additional 4 individuals per 
group (Control, mild PD and moderate PD) were prepared as described above. For each individual, 25μg 
of the protein sample, according to Bradford protein assay, was migrated onto an electrophoresis gel 4-
12% Bis-Tris to separate hemoglobin from higher proteins. Following gel staining using Sypro Ruby 
(Thermo Fischer Scientific), the 12kDa band corresponding to the hemoglobin size was cut out and the 
remaining part of the gel further fractioned into 7 slices, exposed to trypsin digestion and peptide 
extraction on a MassPrep liquid handling robot (Waters, Milford, USA) according to the manufacturer’s 
specifications and the protocol of Shevchenko et al. with the modifications suggested by Havlis et al. 
(Havlis et al., 2003; Shevchenko et al., 1996). For specific details on protein analysis purification, please 
refer to supplementary material. Spectra of peptides were searched against a human protein database 
(Uniprot Complete Proteome, taxonomy Homo sapiens – 83512 sequences) using the Andromeda search 
engine included in MaxQuant software version 1.5.5.1. (Cox and Mann, 2008). MaxQuant was also used 
to validate proteins and peptides at a 1% False Discovery Rate using a target/decoy database search as 
well as to undertake a Label Free Quantification of the identified proteins using the ‘match between 
runs’ option.
Statistical analyses 
All statistical analyses were performed by a qualified statistician and details pertaining to these analyses 
for each experiment are provided in the supplementary material.
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RESULTS 
Optimizing EV detection and the demonstration of reproducibility 
While we performed EV analyses in plasma, we ensured that reproducibility of EV identification and 
labeling was robust. For this, we undertook a series of control experiments to properly set the EV gate 
and fluorescent silica beads of 100nm (Red), 500nm (Blue) and 1000nm (Yellow) were acquired on a flow 
cytometer Canto II modified with a FSC-PMT small particle option (Figure S2A-C). The acquisition was 
performed at low speed at an approximated rate of 10μl/ml. The established EV gate was used for all 
experiments. Serial dilutions of EEV (1, 2, 4 and 10) were also undertaken to confirm the linearity of the 
quantification. FSC-PMT/SSC gates of PFP stained with annexin V fluorescent conjugate (a ligand of 
phosphatidylserine) and respective fluorochrome-conjugated antibodies directed against erythrocyte 
(CD235a+), endothelial (CD31+/CD41-), platelet (CD41+) and leukocyte (CD14+CD45+, monocytes; 
CD15+CD45+, granulocytes)-derived EVs were carefully established.
We further completed numerous controls to ensure specific EV labeling. We first determined that 
treatment with the ion chelator EDTA inhibited the binding of annexin V to phosphatidylserine. We 
observed minimal background using antibodies in the absence of PFP. Subsequently, EV sensitivity to 
0.5% triton was assessed. Under these conditions, the membrane of the EVs is dissolved while protein 
aggregates are left intact (György et al., 2011). Results show that vast majority of EVs positive for their 
own fluorochrome-conjugated antibodies were eliminated by detergent (Figure S2D-F). Finally, we 
conducted a test-retest assay where two PFP samples per subject were collected approximately 2 hours 
apart in 25 healthy individuals. All samples were tested in duplicate and minimal inter-sample variability 
was observed (16% ± 7%) (Figure S2G).
In addition to full blood count, and as a precautionary measure, hematocrit, mean corpuscular 
hemoglobin and mean corpuscular volumes were evaluated and showed similar values between groups 
(Figure S3A). C-reactive protein quantifications were also obtained for all participants and revealed no 
differences between groups (Figure S3B). We did, however, observe a significant increase in EEV 
concentration in the PFP of individuals with diabetes and those suffering, or having suffered, from cancer 
(data not shown) and thus these participants were excluded from our analyses. PFP samples with 
elevated free hemoglobin (>45 000ng/ml), potentially due to hemolysis during blood sampling, were also 
excluded from further EEV-related analyses (Figure S3C), which account for the small discrepancies 
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between the total number of participants initially recruited and those reported in each analysis.
Increase in erythrocyte-derived EV in PD patients is not a diagnostic tool  
Once all the controls established and verified, we collected and carefully analyzed blood samples from 
patients with PD (n=60) along with age/sex-matched healthy Controls (n=37) (Table 1). Full blood counts 
were performed on each sample but did not reveal any differences in the number of platelets, 
leukocytes, monocytes, granulocytes except for erythrocytes, where a small significant difference 
(p=0.049) was seen between PD patients and Controls (Figure 1A). We then labeled each cell type as well 
as each EV population present in plasma to generate accurate counts of EV by FACS. A series of specific 
labelings highlighted a notable increase in the mean number of EEV in PD patients with respect to their 
age- and sex-matched healthy Controls (p=0.04; Figure 1B-C). None of the EV derived from the other 
blood cell populations showed differences between PD and Controls. 
Based on this observation, we evaluated the diagnostic value of EV for PD by taking a closer look at the 
data distribution. However, this uncovered that only 5 patients were responsible for this significant 
difference (Figure 1C, red inset). Further investigation, using a diagnostic accuracy test, revealed that the 
relevant proportion of the area under the Receiver Operating Characteristic (ROC) curve was 0.508 (data 
not shown), implying that the number of EEV could not be used as a discriminant between PD patients 
and healthy Controls. This was also confirmed by performing a Bayesian analysis of the data 
demonstrating that the proposed predictor of the onset of PD would be correct in less than 1% of the 
cases (data not shown). We obtained a similar result when we separated the patients into mild and 
moderate states according to their UPDRS scores or by cohort (data not shown). 
EV counts and clinical features 
Despite the absence of a diagnostic difference in EEV counts, we explored whether there could be a 
relationship between the number of EEV and clinical measures such as H&Y stage, BDI, MMSE and ACE, 
but we found no significant correlations (data shown for H&Y, Figure 2A). However, preliminary analyses 
revealed a correlation of R2=0.37 with a p value of 0.0056 when plotting EEV counts/erythrocytes 
according to the UPDRS clinical rating scales (Figure 2B). In depth statistical analyses further revealed 
intriguing, but striking correlations between the number of vesicles derived from the red blood cells of 
PD patients and their total UPDRS (Figure 2C). Statistical linear regression analysis was performed for 
each group and the R2 values obtained demonstrated that in both cases, at least 87% of the variation in 
the total number of EEV/erythrocytes was due to the variation of the UPDRS (Figure 2C). Moreover, the 
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results were significant with respect to the p values obtained for each fit as they fell below the 5% 
confidence level. This could not be accounted for by medication, as there was no correlation with the 
patients LEDD (Figure 2D-E). Importantly, these results were then corroborated in an independent 
cohort of 42 PD patients where the correlations yielded an R2=0.05 and a p value of 0.15 when plotting 
EEV counts/erythrocytes against scores obtained with the UPDRS clinical rating scale (Figure S4A). 
In contrast to PD, correlation analyses failed to reveal an association between the number of EEV and HD 
stage using the UHDRS score (Figure S5). 
Proteomic signature of EEV in PD 
Given that these correlations are based on a small number of patients (cohort 1; n=19 and cohort 2; 
n=42), we sought to corroborate these results by examining the specific protein signature of EEV from 
mild and moderate PD patients (with respect to their UPDRS scores) and age-matched Controls. Given 
the significant amounts of hemoglobin within erythrocytes that could mask the true nature of the 
protein signature in EEV, we performed a label free quantitative proteomic analysis by nanoLC/MSMS 
(Wither et al., 2016) using two distinct approaches: with and without hemoglobin (Figure 3A-B). By 
removing hemoglobin, we identified a total of 818 proteins in comparison with 356 when we did not 
undertake this methodological step (refer to Table S3 for complete list of proteins) – a modification 
which is clearly needed to give a much more accurate evaluation of the protein content of EEV. 
Additionally, a Gene Ontology enrichment analysis on the ‘Cellular Component’ ontology on the two sets 
of identified proteins in comparison with the whole human proteome, revealed that our samples are 
enriched with elements associated with ‘vesicles’ and ‘hemoglobin complex’ (Figure S6).
Out of the 818 proteins identified in the proteome of EEV, 8 had expressions that were significantly 
different in patients with various stages of PD (Figure 3C). Hierarchical clustering, coupled to a heatmap, 
allowed us to group individuals according to stages of disease (Control, mild PD and moderate PD) and 
provided compelling evidence that the 8 proteins identified could also be grouped into three categories. 
Proteins of group I were highly and predominantly expressed in Controls, proteins of group II were highly 
and predominantly expressed in mild PD patients and proteins belonging to group III were highly and 
predominantly expressed in moderate PD patients (Figure 3D). This data set was further confirmed by 
volcano plots (Figure 3E). 
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Finally, we assessed whether -Syn – which is not only the main component of Lewy bodies but is highly 
expressed in most blood cells – was differentially expressed in normal vs. diseased conditions. For this, 
we opted to use scanning electron microscopy, but this did not reveal any morphological changes 
between resting and activated erythrocytes in either condition (Figure 4A). We further used transmission 
electron microscopy to quantify the number of EEV containing -Syn and phosphorylated (serine 129) 
forms of the protein, but again there were no significant differences between PD patients and age- and 
sex-matched healthy Controls (Figure 4B-C). Quantified -Syn levels in EEV from PD patients and 
Controls using commercial ELISA kits corroborated these results (Figure 4D). 
DISCUSSION 
The primary goal of our study was to provide an accurate description of EV in PD patients. In order to do 
this, we took into account all relevant technical parameters and refined a number of approaches that 
may have been contentious in previous publications. These technical improvements included: 1) better 
methods to clearly identify EV when using FACS; 2) specific labeling to determine, with precision, the cell 
origin of the EV; 3) the demonstration of minimal test-retest variability intra-patient; 4) the deletion of 
hemoglobin from the samples for proteomic analyses which, as suspected, revealed numerous proteins 
which currently remain unidentified and finally, 5) the development of a user-friendly test which has the 
potential to be easily performed by western blots in any laboratory contexts using just a few microliters 
of blood. Once we had established the protocols for EV characterization, the second objective of this 
study was to explore the potential biomarker value of EVs in PD. We found that EEV counts did map to 
disease stage, a finding that was corroborated by a unique protein signature in control subjects, mild and 
moderate PD patients. Our observations were then confirmed in a second independent cohort of PD 
patients, showing that our findings are robust and thus could have widespread applicability for helping 
stage PD patients in the future. 
Blood counts were systemically performed in all patients, EV identification was replicated using the most 
accepted and standardized methods of repetition, stringent controls (microbeads, antibodies negative 
control, EDTA and Triton) (Rousseau et al., 2015) and complex combinations of antibodies which allowed 
for the specific labeling of vesicles. Standard techniques used to analyse EVs (e.g. ultracentrifugation 
followed by immunoblotting) requires several days and a considerable amount of cells to isolate EVs. 
However, quantification by flow cytometry takes only 1 day and requires a relatively small quantity of 
plasma (Konoshenko et al., 2018). We further demonstrated minimal test-retest variability. Sequential 
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analyses of EV during the same day from the same individual/sample (intra-assay variation) has been 
reported to vary between 1-12% (Vestad et al., 2017). For example, circadian rhythm has been reported 
to influence the activation of platelets and therefore influence EV derived from these cells (Scheer et al., 
2011). In recent studies, counts of microvesicles derived from platelets across different flow cytometry 
platforms showed an inter-laboratory variability ranging between 28% and 37% (Vogel et al., 2016). In 
our hands, variability measures ranged between 1-30%, with an average at 16% ±7%, indicative of strong 
reproducibility.
While proteomic studies of EEV have been previously reported, their description was limited to 270 
proteins (Bosman et al., 2012, 2008). We herein report on an improved method to perform this type of 
analyses in blood samples by removing hemoglobin; a large protein that can easily mask others within a 
protein signature. Indeed, the high dynamic range of protein concentrations in erythrocytes and their 
EEV, due to the abundance of hemoglobin, decreases the capacity of the mass spectrometer to detect 
signals corresponding to low abundance proteins. Analyzing the hemoglobin, separately from proteins of 
other molecular weights, allowed us to go deeper into the EEV proteome, identifying 129% more 
proteins than in the initial analysis. It is important to reiterate that our proteomic analyses were 
performed using very stringent parameters, which included a minimum of 2 peptides per protein and p 
values of less than 0.05 with an absolute z score of 1.96, corresponding to values outside of the 95% 
confidence range. Finally, our volcano plots and heatmap analyses revealed high specificity of the 
identified proteins for each group with nodes ranging between 80 and 90%. With this, reproducibility of 
our proteomics data is high despite the smaller sample size (analyses performed on 3 pools of 3 samples 
per group and subsequently on 4 individual samples per group). Reports of the role of these proteins in 
PD are rare. However of interest, QDPR has been reported to be essential to the bisosynthesis of 
norepinephrin and serotonin (Kaufman et al., 1975). ABHD14B have been shown to be dysregulated in 
mice following a levo-dopa treatment (Charbonnier-Beaupel et al., 2015) and that mARNs for CNRIP1 are 
diminished in the striatum of a primate model of PD (Zeng et al., 1999). Finally, genetic variants of USP24 
are associated to PD risk factors (Li et al., 2006) while another study of blood genetic profile revealed 
that ATP5A1 is down regulated in idiopathic PD patients (Shamir et al., 2017).
Although staging of PD is often done using the H&Y clinical scale, we sought to use the UPDRS given its 
more comprehensive coverage of disease features – an approach that has recently been validated 
(Martínez-Martín et al., 2015). Using these scores in our initial study, we found that mild PD patients – 
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with a UPDRS score lower than 37 – have an increased number of EV (correlations = 0.886); and that the 
exact same pattern then repeats itself with patients who had UPDRS scores between 37 and 75 
(correlations = 0.873) with a marked resetting of the number of EVs between these two stages. In this 
study, which was undertaken using patients in research clinics, patients with advanced disease (75 
UPDRS) were not recruited in large numbers because they have difficulty making it to the clinics. In order 
to further validate this finding, we undertook a second study in another 42 patients with PD, which also 
included patients with more advanced disease. In this additional independent cohort, we demonstrated 
that we can replicate, very closely, what we found in the first cohort. Namely, mild patients fell between 
the UPDRS scores of 0 – 39, moderate patients between 29 – 57 and severe patients (which we did not 
analyze in the first cohort), between 57 – 74 and that there EV changes paralleled that which we saw in 
our initial study. The overlapping zone is likely due to a number of factors including the fact that 1) this 
new cohort was scored by a different clinician than our first cohort. Indeed, despite the fact that 
neurologists are trained to score patients in a similar fashion, the UPDRS remains a subjective measure 
that can vary between clinicians, even when they are been validated as a rater using the MDS training 
videos. 2) The FACS sorting apparatus we use to quantify EEV does generate a small percentage of 
variability (around 8%) between runs (data not shown). 3) We opted to test patients ON medication. It is 
therefore possible that the patient tested in the morning, who has just recently taken his medicine, 
scores slightly differently on the UPDRS than the patient who has taken in meds in the morning but were 
assessed late afternoon. 
The bi-modal distribution revealed by the correlation analysis is intriguing but it would be very difficult to 
establish a definite cut-off between groups. The UPDRS is based on a questionnaire of more than 70 
different questions which are all based on a subjective assessment of the patient. A patient falling at the 
border of mild and moderate stage PD may be very difficult to categorize. We have already ruled out 
medication (in particular LEED) and a number of co-morbidities (depression, cancer, diabetes, 
hypertension, hypercholesterolemia, asthma, allergies) as contributing to this. It is important to note 
that, while the R2 values are very impressive, the samples used for each group (cohort 1; n=19 and 
cohort 2; n=42) are undersized with respect to the classical Pearson’s chi-squared test. Further 
investigation with a larger cohort should therefore achieve more confident results which we are doing 
now. 
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Overall, we have identified a novel biomarker in the blood of patients with PD that seems to correlate 
with disease stage and which is derived from 2 measures: the number of EEV/erythrocytes and the 
expression of 8 different proteins. The biological reasons as to why we find these correlations is still 
unresolved as is the pathological significance of the protein signature we identified. Nevertheless, our 
findings are robust and reproducible and further support recent findings that plasma EV derived from 
the CNS and containing α-syn correlate with the UPDRS scores in PD patients (Shi et al., 2014). Our 
results unveil a useful new biomarker, and while the EEV counts used a particular type of flow cytometer 
that is not necessarily accessible to all laboratories, the identification of specific proteins that match 
clinical stages of PD implies that these could be more easily tested/detected in samples using simple 
western blots. If replicated in other studies, we would then have a biomarker that could be easily tested 
in any laboratories or clinical context. (Maere et al., 2005; Nguyen et al., 2016; R Core Team, 2016; 
Suzuki and Shimodaira, 2006)
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Figures legends
Table 1. Participant clinical information – PD cohort. Disease severity as measured using the H&Y scale 
(score): Mild (1-1.5); Moderate (2-2.5); Severe (3-3.5). *p < 0.05 vs. CTRL. Statistical analyses were 
performed using a Kruskal Wallis test followed by Dunn's multiple comparison test. 
Figure 1. A. Blood cell quantification. Full blood counts performed in PD patients (n=57) revealed no 
significant differences in the total number of any cell type between patients and their respective healthy 
sex- and age-matched CTRL (n=37), except for erythrocytes. Statistical analyses were performed using 
unpaired t-tests when data followed normal distributions according to the Shapiro-Wilk test or Mann-
Witney in cases of non-normality. B. Cell-derived EV quantification. The quantification of EV in platelet-
free plasma of PD patients and controls was performed by high-sensitivity flow cytometry. 
Phosphatidylserine was evaluated with Annexin V binding. The complete blood count was obtained at 
the time of blood sampling for 35|37 Controls and 57|59 PD and was used to calculate the EV per cell 
ratio. Statistical analyses were performed using a Two-Way ANOVA. * For erythrocyte-derived EV 
quantification, 1 outlier (determined using Grubbs’ method with alpha=0.0001) was removed. C. 
Diagnostic Value. Distribution plots of CD235a+ EV/total number of erythrocytes between PD and 
healthy sex- and age-matched CTRL (PD, n=42; CTRL, n=24). Abbreviation: CD235a-45-41-31-15-14, 
cluster of differentiation; CTRL, Control; EV, extracellular vesicle; EEV, erythrocyte-derived extracellular 
vesicle; PD, Parkinson’s disease; PS, phosphatidylserine; UPDRS, Unified Parkinson’s Disease Rating Scale.
Figure 2. Relationship between EEV and clinical measures of PD. A. Absence of correlations between 
EEV/Erythrocyte counts and H&Y stage. B. Correlations between EEV/Erythrocyte counts with total 
UPDRS scores. C. Robust correlations between the number of EEV/total number of erythrocytes and 
UPDRS scores (PD, n=20, from the UK cohort exclusively since the Quebec cohort did not have recent 
UPDRS scores available). D. EV/erythrocytes ratios, UPDRS scores and LEDD values for all PD patients 
used in the correlation analyses. E. Absence of correlation between the number of EEV and 
LEDD. Correlations reported were determined using Pearson’s goodness-of-fit test. Abbreviation: 
CD235a, glycophorin A; CTRL, Control; EEV, erythrocyte-derived extracellular vesicle; H&Y, Hoehn and 
Yahr; LEDD, Levodopa equivalent daily dose; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease 
Rating Scale.
Figure 3. A-B. Proteomic analyses with and without hemoglobin. To ensure the specificity of the protein 
signature detected in EEV, we performed proteomic analyses using two distinct methodologies. A. The 
first set of analyses by nanoLC-MS/MS and Label Free Quantification was performed on the complete 
proteome of the EEV, yielding 356 proteins. B. The second set of analyses was also performed on the 
entire EEV proteome but this time, isolating hemoglobin and quantifying the proteins present in both 
fractions. This approach uncovered 708 proteins in the EEV proteome with an additional 110 proteins in 
the hemoglobin fraction for a total of 818 proteins, indicating that removing hemoglobin provides a 
much more accurate evaluation of the protein content of EEV. C-D. Specific protein signature of EEV in 
PD patients. B. NanoLC-MS/MS Label-free analysis of EEV in PD patients and healthy age-matched CTRL 
revealed a total of 818 proteins, of which 8 had an expression that was significantly different as a 
function of PD stage (C). The proteins/genes have been further separated into 3 groups in relation to 
their variations in comparison to CTRL (Group I), mild PD (Group II) or moderate PD (Group III). D. 
Heatmap establishing correlations between disease stages and the abundance of the variable proteins. 
Cold and hot colours represent low and high correlation levels, respectively. The AU p value is indicated 
for each node. Protein level changes were determined by Welch’s test p value ˂ 0.05 and absolute value 
of z-score ˃ 1.96, *p<0.05, **p<0.01. Abbreviations: AU, Approximately Unbiased; CTRL Control; PD, 
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Parkinson’s disease. E. The protein ratios (log2(ratio)) of the three comparisons (mild PD/CTRL, moderate 
PD/CTRL and moderate PD/mild PD) were plotted over the corresponding Welch’s test p value (-log10(p-
value)). The graphs display a V shape, as expected, and only the proteins falling outside the limits of a p 
value < 0.05 and absolute value of z-score > 1.96 (identified by black lines) were considered as variant 
proteins (red dots). Two variant proteins were excluded given that they were quantified using only one 
peptide. Abbreviations: ABHD14B, alpha/beta hydrolase domain-containing protein 14B; AIDA, axin 
interactor dorsalization-associated protein; AKR1A1, alcohol dehydrogenase NADP+; ATP5A1, ATP 
synthase subunit alpha mitochondrial; CNRIP1, cannabinoid receptor-interacting protein 1; CTRL: 
Control; NADSYN1, glutamine-dependent NAD(+) synthetase; USP24, ubiquitin carboxyl-terminal 
hydrolase 24; PD, Parkinson’s disease; QDPR, Quinoid Dihydropteridine Reductase.
Figure 4. Detection of normal and phosphorylated α-Syn in EEV. A. Representative scanning electron 
micrographs of resting and activated erythrocytes in both PD patients and healthy sex- and age-matched 
CTRL. Scale bar: 2μm. B. Representative transmission electron microscopy images of immunogold 
labeling for -Syn and -Syn pS129 in activated erythrocytes and EEV (some examples delineated by 
dotted lines). Arrowheads point to positive immunolabeling for either -Syn or -Syn pS129. Scale bar: 
100nm. C. Quantification of α-Syn in EEV as detected by transmission electron microscopy and expressed 
as the percentage of EEVs positive for α-Syn/total number of EEV in healthy sex- and age-matched CTRL 
and PD patients (n=100 erythrocytes sampled in n=3 CTRL and n=3 PD). D. Quantification of α-Syn in EEV 
by ELISA assays in healthy sex- and age-matched CTRL, mild and moderate stage patients (n=4 
erythrocytes per group; n=13 EEV per group) showed no measurable changes in α-Syn levels between PD 
and healthy sex- and age-matched CTRL. Statistical analyses were performed using a Mann-Whitney U 
test (C) or a Kruskal-Wallis test (D). Abbreviations: α-Syn, α-synuclein; -Syn pS129, -synuclein 
phosphorylated Serine 129; CTRL, Control; EEV, erythrocyte-derived extracellular vesicle; PD, Parkinson’s 
disease.
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Supplementary figures 
Figure S1. Erythrocyte and EV implication in PD: summary of the literature. The search for a reliable 
biomarker in PD has included investigations on neuronal cells in specific in vitro systems, on cellular 
elements within the circulatory system, the CSF and urine with a targeted interest on the expression of 
α-Syn. However, none of these studies have convincingly identified a robust marker of PD. 
Abbreviations: αSyn, α-synuclein; CAT, Catalase; GPx, glutathione peroxidase; L1CAM, L1 cell adhesion 
molecule; LRRK2, Leucine-rich repeat kinase 2; RBC, red blood cells; SOD, superoxide dismutase; ✓ 
presence;  increase;  decrease.
Figure S2. Optimization of EV detection: controls for flow cytometry. Controls for EV identification. A. 
To properly set the EV gate, fluorescent silica beads of 100nm (Red), 500nm (Blue) and 1000nm (Yellow) 
were acquired on a flow cytometer Canto II modified with a FSC-PMT small particle option. B. Serial 
dilutions of EEV (1, 2, 4 and 10) were used to confirm the linearity of the quantification. C. FSC-PMT/SSC 
gates of PFP stained with annexin V and respective fluorochrome-conjugated antibodies directed against 
erythrocyte (CD235a+), endothelial (CD31+/CD41-), platelet (CD41+) and leukocyte (CD14+CD45+, 
monocytes; CD15+CD45+, granulocytes)-derived EVs. Controls for EV labeling. D. Treatment with the ion 
chelator EDTA inhibited the binding of annexin V to phosphatidylserine. E. Minimal background was 
observed using antibodies in the absence of PFP and was subtracted from all subsequent EV 
quantifications. F. EV sensitivity to 0.5% triton was further assessed G. Reproducibility of EEV counts over 
time. EEV/Erythrocytes counts and CV% obtained for the 25 additional participants. Each subject 
provided 2 samples at two distinct time points (C#-1: Patient#-Time 1, C#-2: Patient#-Time 2) yielding 2 
measurements per patient. Abbreviations: AnnV, annexinV; EV, extracellular vesicle; EEV, erythrocyte-
derived extracellular vesicle; FSC PMT-H, forward scatter photomultiplier tube; PBS, phosphate buffered 
saline; PFP, platelet free plasma; SSC-H, side scatter.
Figure S3. Blood counts and exclusion criteria. A. Evaluated hematocrit, mean corpuscular hemoglobin 
and mean corpuscular volumes were similar between groups (PD, n=43; CTRL, n=24). B. CRP (indicative 
of an inflammatory response) and free hemoglobin (indicative of hemolysis) (C) were further quantified 
in the PFP (PD, n=59; CTRL, n=37). Individuals presenting with levels exceeding 45 000ng/ml were 
excluded from the study to remove the possibility that these factors contributed to increased EEV 
concentrations. Statistical analyses were performed using Kruskal-Wallis test (A-B) and Mann-Whitney U 
tests (C-E). Abbreviations: CTRL, controls; CRP, C-reactive protein; PD, Parkinson’s disease; PFP, platelet-
free plasma.
Figure S4. Relation between EEV and clinical measures of PD in additional cohort. A. Correlations 
between EEV/Erythrocyte counts with total UPDRS scores for mild (B), moderate (C) and severe patients 
(D) E. EV/erythrocytes ratios, UPDRS scores and LEDD values for all PD patients used in the correlation 
analyses. F. Absence of correlation between the number of EEV and LEDD. Correlations reported were 
determined using Pearson’s goodness-of-fit test.
Figure S5. A. Cell-derived EV quantification of – HD cohort. The quantification of EV in platelet-free 
plasma of HD patients and controls was performed by high-sensitivity flow cytometry. 
Phosphatidylserine was evaluated with Annexin V binding. The complete blood count was obtained at 
the time of blood sampling for 53|54 CTRL, 10 pre-manifest and 48|50|51 HD patients and was used to 
calculate the EV per cell ratio. Statistical analyses were performed using Two-Way ANOVA. B. 
Distribution plots of CD235a+/total number of erythrocytes revealed no differences between HD and 
healthy sex- and age-matched CTRL (HD, n=50; Pre-HD, n=10; CTRL, n=52) and C. no statistically 
Lamontagne-Proulx et al., 2018 
24
significant correlations were found between the number of EEV/total number of erythrocytes and 
UHDRS scores (HD, n=42). Correlations were determined using Pearson’s goodness-of-fit test, 
*p<0.05. Abbreviations: ACE, Addenbrooke's Cognitive Examination; BDI, Beck Depression Inventory; 
BDS, Burden of Disease Score; CD235a, glycophorin A; CTRL, Controls; EEV, erythrocyte-derived 
extracellular vesicle; EV, extracellular vesicle; HD, Huntington’s disease; H&Y, Hoehn and Yahr; MMSE, 
Mini-Mental State Examination; Pre-HD, Pre-manifest; PS, phosphatidylserine; TFC, Total Functional 
Capacity; UHDRS, Unified Huntington’s Disease Rating Scale. 
Figure S6. A Gene Ontology enrichment analysis was performed on the Cellular Component ontology 
using BinGO software. The list of 356 identified proteins in the entire EEV (A) and the list of the 818 
identified proteins when hemoglobin was analyzed separately (B) were compared to the whole human 
proteome (reference list). Circle size is proportional to the number of proteins matching the 
corresponding GO term and the color scale corresponds to the p value of enrichment (darker orange 
corresponds to greater statistical enrichments).
Table S1. Participant clinical information – HD cohort. Disease severity levels in relation to the TFC 
scale: Stage 1 (11-13); Stage 2 (7-10); Stage 3 (3-6); Stage 4 (1-2); Stage 5 (0). Disease severity was 
evaluated within 6 months of blood sampling. Comorbidities were determined from medical information 
reported by the participant or caregiver. Blood cell quantification. Full blood counts performed in HD 
patients at different stages of the disease (Pre-HD, n=10; Stage 1, n=15; Stage 2, n=12; Stage 3, n=11; 
Stage 4, n=10; Stage 5, n=2) revealed no significant differences in the total number of any cell type 
between patients and their respective healthy sex- and age-matched CTRL (n=54), except for 
erythrocytes. Statistical analyses were performed using a Kruskal Wallis test followed by Dunn's multiple 
comparison test. 
Table S2. Participant clinical information – PD cohort no.2. Disease severity as measured using the 
UPDRS scale (score): Mild (0,39); Moderate (29,73); Severe (57,74). *p < 0.05 vs. CTRL. Statistical 
analyses were performed using a Kruskal Wallis test followed by Dunn's multiple comparison test. 
Table S3. Complete list of proteins identified in the EEV proteome. Lists of the protein groups identified 
by LC-MS/MS analysis using Andromeda/MaxQuant search engine in the Uniprot Complete Proteome 
Homo sapiens database for the non-depleted sample (356 proteins) (A) or when hemoglobin was 
analyzed separately (818 proteins) (B). The lists were filtered at 1% False Discovery Rate using a 
target/decoy database search.




SI Materials and methods
Preparation of platelet-free plasma and EV labeling
For all experiments, diluted annexin-V buffer (BD Pharmingen, Mississauga, ON, Canada) and phosphate 
buffered saline (PBS) were filtered on 0.22µm pore size membranes (PALL, Mississauga, ON, Canada). To 
quantify EV according to their cell of origin, the following surface markers were used: CD235a+ 
(erythrocytes) (5µl), CD31+/CD41- (endothelial cells) (1µl), CD41+ (platelets) (5µl), CD45+ (leukocytes) 
(3µl), CD45+CD14+ (monocytes) (10µl), and CD45+CD15+ (granulocytes) (2µl), with or without annexin-V 
staining (5µl). PFP (5µl) was incubated with Phenylalanyl-prolyl-arginyl Chloromethyl Ketone (PPACK) 
10mM (Calbiochem, Etobicoke, ON, Canada) for 5 minutes followed by a 30-minute incubation with 
antibodies and annexin-V in a final PBS volume of 100µl, all at room temperature. Finally, samples were 
diluted to a final volume of 2ml prior to FACS analysis. The following antibodies were purchased from BD 
Pharmingen and used for all analyses: FITC-conjugated mouse anti-human CD235a (clone GA-R2 (HIR2), 
1/20), PE-conjugated mouse anti-human CD31 (clone WM59, 1/100), V450-conjugated mouse anti-
human CD41a (clone HIP8, 1/20), V450-conjugated mouse anti-human CD45 (clone HI30, 1/33), APC 
mouse anti-human CD14 (clone M5E2, 1/10), PE-conjugated mouse anti-human CD15 (clone HI98, 1/50), 
V450- and PerCP-CyTM5.5-conjugated annexin-V (1/20). 
Flow cytometry quantification
The acquisition of EV was performed at low speed at an approximated rate of 10μl/min. To determine 
background noise levels, antibody mixes were incubated in the absence of PFP sample and unlabeled PFP 
was used as a negative control. Every sample was re-identified to ensure that the experimenter was 
blind to clinical status. 
Production and purification of EEV
Briefly, the erythrocyte pellet was activated with 3 volumes of calcium ionophore solution (150mM NaCl; 
10mM Tris-HCl; 1mM CaCl2; 5μM ionophore A23187 (Sigma, St Louis, MO)) for 30 minutes at 37°C. 
Calcium ionophore is key to EV biogenesis. It participates in the activation and inhibition of proteins and 
phospholipids at the cell membrane. Calcium ionophore A23187 induces a change in the concentration 
of calcium which leads to vesicle formation. In contrast to water and freezing, which are frequently used 
to provoke the release of EEV, calcium ionophores avoid the destruction of the erythrocyte membranes 
(Nguyen et al., 2016). The activation was stopped by the addition of 5mM EDTA. Remaining erythrocytes 
were pelleted at 15 000g for 20 minutes. The EEV were centrifuged at 20 000g for 90 minutes and 
washed once in PBS. The EV pellet was re-suspended in PBS and frozen at -80°C until further analyses.
Scanning electron microscopy
Preparations of erythrocytes (5μl) were fixed in 2% paraformaldehyde and 2.5% glutaraldehyde in PBS 
buffer at least 24 hours before standard dehydration. Samples were washed 3 times for 10 minutes with 
sodium cacodylate buffer (0.1M, pH 7.3) and fixed with 1% osmium tetroxide in sodium cacodylate 
buffer for 90 minutes. Subsequently, samples were washed and processed in 50%, 70%, 90% and 100% 
EtOH for dehydration (10 minutes/step). Finally, samples were soaked in two subsequent baths of 100% 
EtOH, for 40 minutes and 10 minutes, air-dried overnight and coated with palladium. Observations were 
completed using a JEOL 6360LV scanning electron microscope (JEOL, Peabody, MA, USA).
Transmission electron microscopy
Preparations of EEV (30μl) and activated erythrocytes (5μl) were fixed in 2% paraformaldehyde at least 
24 hours before being dehydrated and sealed in LR white. Slices of LR white were placed on a 
Formvar/carbon-coated grid and processed for immunolabeling. The tissues mounted on grids were 
blocked in 0.5% BSA-c (Aurion, Wageningen, The Netherlands) in HBSS and incubated for 120 minutes 
with rabbit anti--Syn antibody (Abcam, Toronto, ON, Canada) or rabbit anti--Syn (phospho S129) 
antibody (Abcam, Toronto, ON, Canada), both diluted at 1:250 in HBSS and washed several times with 
distilled water. Finally, the grids were incubated for 60 minutes with an anti-rabbit IgG conjugated to 
6nm gold particles (EMS, Hatfield, PA, USA) diluted at 1:200, washed several times with distilled water 
and then fixed in 2.5% glutaraldehyde (EMS, Hatfield, PA, USA) in HBSS for 15 minutes. For this last step, 
the grids were treated with 3% uranyl acetate–0.075 M oxalate (pH 7.0) (EMS, Hatfield, PA, USA) for 1 
minute, which was followed by several washes in distilled water. All staining experiments included 
negative controls where the primary antibody was omitted from the incubation media. Observations 
were completed with a TECNAI Spirit G2 transmission electron microscope at 80kV (FEI, Hillsboro, OR, 
USA).
Mass spectrometry analysis and label free protein quantification 
The extracted peptides from the 7 slices of the same individual were pooled and analyzed by nanoLC-
MS/MS. The excised hemoglobin gel slices were also analyzed in the same conditions. One µg of each 
individual sample was injected on a Dionex UltiMate 3000 nanoRSLC system (Thermo Scientific) 
equipped with a nanoviper Acclaim Pepmap100, C18, 3µm, 75µm x 50cm column (Thermo Scientific) 
connected to the nanoelectrospray source of an Orbitrap Fusion mass spectrometer (Thermo Scientific). 
The peptides were eluted at 300nL/min using an acetonitrile gradient of 90 minutes with the mass 
spectrometer operating in the Data Dependent Acquisition mode. Peptide masses were measured in MS 
spectra detected in the orbitrap at 120K resolution. MSMS fragmentation spectra of peptides were 
generated by Higher energy Collisional Dissociation (HCD) and detected in the ion trap. 
Statistical analyses 
Initial statistical analyses (unpaired t-tests when data followed normal distribution according to Shapiro-
Wilk test or Mann-Witney in cases of non-normality) compared the number of each type of blood cells 
(erythrocytes, platelets, leukocytes, neutrophils, monocytes, lymphocytes) in control groups and patients 
of all stages of the UK to the Canadian cohorts. Comparison between each type of EV from every cells 
including erythrocytes, platelets, leukocytes, neutrophils, monocytes, lymphocytes and endothelial cells 
were performed using Two-Way ANOVA. This revealed no statistical differences between groups, 
allowing us to pool cohorts for subsequent analyses. Statistical analyses pertaining EEV quantification 
were performed using The Statistics and Machine Learning Toolbox provided by MathWorksTM under 
MATLABTM platform using the MATLABR2015a version. Results obtained include the scatter plots, 
classical least-square linear regressions, R-squared and p values, as well as Pearson’s goodness-of-fit. 
Interval cut-off values were determined using a loop program developed in MATLABTM. Model 
diagnostics, including residual behaviour and homoscedastivity, were obtained using the same Toolbox. 
Further details on the statistical tests chosen are described directly in the result section. For -Syn 
quantification, data were first tested for normality using the D’Agostino & Pearson normality test. 
Comparisons between groups were obtained by Mann-Whitney U test or Kruskal-Wallis ANOVA and 
performed using Prism 6.0 (GraphPad Software, LaJolla, CA). For proteomic analyses, the ‘Intensity 
values’ contained in the output ‘proteingroup.txt’ file of MaxQuant were used to quantify each identified 
protein in each individual sample. The values were normalized by the median of each column (all 
intensity values of proteins for one sample). The missing values were imputed with a noise value 
corresponding to the 1-percentile of each sample column. For each comparison between two groups 
(Control, mild PD or moderate PD), proteins with too many imputed values where considered not 
quantifiable (a minimum of three not-imputed values in one of the 2 groups are required). A protein 
ratio was calculated between the two groups using the average of intensity values in each group. Finally, 
a statistical Welch's test was performed between the two groups. The protein ratios were transformed 
into log2(ratio) then centered by calculation of a z-score (z-score = (x - µ)/σ). A protein was considered as 
variant if it fulfilled the following criteria: minimum of 2 peptides quantified, Welch’s test p value ˂ 0.05 
and absolute value of z-score ˃ 1.96 (corresponding to values outside of the 95% confidence interval). 
The Gene Ontology enrichment analysis on the identified proteins was performed on the Cytoscape 
platform (v. 3.4.0) using the BinGO software version 3.0.3  against all human genes with GO annotation 
(Uniprot-GOA generated 2015-06-22) (Maere et al., 2005). Enrichment was calculated by a 
hypergeometric test and Bonferroni Family-Wise Error Rate (FWER) was used to correct for multiple 
testing. The data for the resulting 8 proteins was standardized, hierarchically clustered and visualized as 
a heatmap by using the statistical framework R (R Core Team, 2016). The robustness of the nodes was 
evaluated by computing Approximately Unbiased (AU) p values using the R package pvclust (10000 
bootstraps, average method and correlation-based dissimilarity matrix) (Suzuki and Shimodaira, 2006).






Table 1. Participant clinical information – PD cohort. Disease severity as measured using the H&Y scale 
(score): Mild (1-1.5); Moderate (2-2.5); Severe (3-3.5). *p < 0.05 vs. CTRL. Statistical analyses were 
performed using a Kruskal Wallis test followed by Dunn's multiple comparison test. 
Table 1.  Participant clinical information
PD cohort
PD Patients – Stages of diseaseCTRL
Unknown Mild Moderate Severe p value
n 37 7 12 33 8
Age 66.8 69.8 66.7 71.1 75.0* 0.04
Gender F (M) 18 (19) 1 (6) 6 (6) 16 (17) 0 (8) 0.05
Disease severity
Hoehn & Yahr (n) 1 ± 0.3 (12) 2 ± 0.2 (33) 3 ± 0.5 (8) <0.0001
UPDRS (n) 38 ± 11 (6) 52 ± 19 (17) 73 ± 20 (6) 0.02
MMSE (n) 29 ± 2 (7) 29 ± 1 (19) 26 ± 3 (6) 0.01
BDI (n) 3 ± 2 (6) 4 ± 2 (17) 13 ± 7 (4) 0.03
ACE (n) 96 ± 4 (6) 92 ± 7 (17) 84 ± 14 (6) 0.13
Comorbidities
Depression 3 1 2 1 2 0.29
Cancer 5 0 3 4 1 0.64
Diabetes 2 0 0 1 2 0.10
Hypertension 10 1 2 10 3 0.76
Hypercholesterolemia 5 0 1 6 1 0.73
Asthma 3 1 1 5 0 0.71
Allergies 2 0 2 6 2 0.28
Blood cell quantification
CTRL Pre-HD Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
Cell type Units
n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD
p value
Erythrocytes 109/ml 54 4.58 0.36 10 4.59 0.36 15 4.75 0.37 12 4.56 0.29 11 4.69 0.44 10 4.76 0.39 2 4.35 0.26 0.44
Platelets 106/ml 54 229 51 10 259 85 15 232 68 12 218 54 11 268 63 10 212 46 2 305 55 0.09
Leukocytes 106/ml 54 6.61 1.60 10 6.97 1.64 15 6.30 1.13 12 7.67 2.97 11 6.97 2.00 10 6.84 2.07 2 5.30 1.56 0.47
Monocytes 106/ml 54 0.51 0.16 10 0.48 0.57 15 0.49 0.50 12 0.55 0.18 11 0.58 0.24 0.51 0.16 2 0.61 0.42 0.79
Table S1. Participant clinical information – HD cohort. Disease severity levels in relation to the TFC scale: Stage 1 (11-13); Stage 2 (7-10); Stage 3 
(3-6); Stage 4 (1-2); Stage 5 (0). Disease severity was evaluated within 6 months of blood sampling. Comorbidities were determined from medical 
information reported by the participant or caregiver. Blood cell quantification. Full blood counts performed in HD patients at different stages of 
the disease (Pre-HD, n=10; Stage 1, n=15; Stage 2, n=12; Stage 3, n=11; Stage 4, n=10; Stage 5, n=2) revealed no significant differences in the total 
number of any cell type between patients and their respective healthy sex- and age-matched CTRL (n=54), except for erythrocytes. Statistical 
analyses were performed using a Kruskal Wallis test followed by Dunn's multiple comparison test. 
Table S1.  Participant clinical information
HD cohort
HD Patients – Stages of disease
CTRL
Pre-HD Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 p value
n 55 11 15 13 12 10 2
Age 55.0 37.5 53.1 54.2 58.3 58.1 55.5 0.02
Gender F (M) 31 (22) 6 (5) 5 (10) 4 (9) 8 (4) 7 (3) 1 (1) 0.26
Disease severity
CAG (n) 28.3 (3) 41.1 (10) 42.3 (13) 42.6 (12) 43.7 (7) 44.3 (7) <0.001
UHDRS (n) 2.7 (11) 15.7 (14) 34.5 (11) 42.9 (12) 55.9 (10) 67.5 (2) <0.001
TFC (n) 13 (16) 13 (11) 12.5 (15) 7.8 (13) 4.3 (12) 1.6 (10) 0 (2) <0.001
BDS (n) 206 (10) 337 (13) 356 (12) 442 (7) 465 (7) <0.001
Comorbidities
Depression 8 1 1 3 6 4 1 0.0497
Cancer 0 0 0 0 0 0 0
Diabetes 3 1 1 1 1 1 0 0.99
Hypertension 4 1 2 1 1 2 0 0.92
Hypercholesterolemia 8 1 1 0 0 1 0 0.32
Asthma 0 0 1 0 0 0 0 0.65
Allergies 3 0 2 2 0 0 0 0.33
Table S2. Participant clinical information – PD cohort no.2. Disease severity as measured using the UPDRS 
scale (score): Mild (0,39); Moderate (29,73); Severe (57,74). *p < 0.05 vs. CTRL. Statistical analyses were 
performed using a Kruskal Wallis test followed by Dunn's multiple comparison test. 
Table S2.  Participant clinical information
PD cohort – cohort 2 
PD Patients – Stages of disease
Mild Moderate Severe p value
n 5 27 10
Age 63.4 68.5 71.3 0.26
Gender F (M) 2 (3) 11 (16) 4 (6) 0.99
Disease severity
UPDRS (n) 27 ± 8 (5) 46 ± 11 (27) 71 (10) <0.0001
Comorbidities
Depression 0 5 1 0.51
Cancer 0 0 0 NA
Diabetes 0 0 0 NA
Hypertension 0 3 0 0.42
Hypercholesterolemia 0 3 0 0.42
Asthma 0 2 0 0.56
Allergies 0 1 0 0.75
Table S3. Complete list of proteins identified in the EVV proteome
A. Uniprot Complete Proteome Homo sapiens database for the non-depleted sample
Protein 
ID Protein names
Gene 
names
Razor + 
unique 
peptides
P02549 Spectrin alpha chain, erythrocytic 1 SPTA1 136
P11277 Spectrin beta chain, erythrocytic SPTB 123
P16157 Ankyrin-1 ANK1 70
P02730 Band 3 anion transport protein SLC4A1 38
P55072 Transitional endoplasmic reticulum ATPase VCP 33
P16452 Erythrocyte membrane protein band 4.2 EPB42 33
P11171 Protein 4.1 EPB41 33
P04040 Catalase CAT 32
Q13228 Selenium-binding protein 1 SELENBP1 29
B4DT77 Annexin;Annexin A7 ANXA7 27
Q8WUM4 Programmed cell death 6-interacting protein PDCD6IP 27
P35612 Beta-adducin ADD2 26
P68871 Hemoglobin subunit beta;LVV-hemorphin-7;Spinorphin HBB 25
Q00610 Clathrin heavy chain 1 CLTC 25
P69905 Hemoglobin subunit alpha HBA1 22
B4DVE7 Annexin A11 ANXA11 20
J3QLD9 Flotillin-2 FLOT2 20
P08758 Annexin A5;Annexin ANXA5 19
P09525 Annexin A4;Annexin ANXA4 18
O75955; Flotillin-1 FLOT1 18
P11142 Heat shock cognate 71 kDa protein HSPA8 18
P32119 Peroxiredoxin-2 PRDX2 17
P00491 Purine nucleoside phosphorylase PNP 17
P27105 Erythrocyte band 7 integral membrane protein STOM 17
P00918 Carbonic anhydrase 2 CA2 17
P23634 Plasma membrane calcium-transporting ATPase 4 ATP2B4 17
C9JIF9 Acylamino-acid-releasing enzyme APEH 17
P00915 Carbonic anhydrase 1 CA1 16
P63261 Actin, cytoplasmic 2 ACTG1 16
Q5VU58 Tropomyosin alpha-3 chain TPM3 16
P30041 Peroxiredoxin-6 PRDX6 16
E7EU23 Rab GDP dissociation inhibitor beta GDI2 16
Q00013 55 kDa erythrocyte membrane protein MPP1 16
E7EV01 Calpain-5 CAPN5 16
J3KPS3 Fructose-bisphosphate aldolase A ALDOA 15
Q08495 Dematin DMTN 15
P23276 Kell blood group glycoprotein KEL 15
P69892 Hemoglobin subunit gamma-2 HBG2 14
P60174 Triosephosphate isomerase TPI1 14
P62258 14-3-3 protein epsilon YWHAE 14
O75326 Semaphorin-7A SEMA7A 14
O75340 Programmed cell death protein 6 PDCD6 13
E7EV99 Alpha-adducin ADD1 13
Q5VZU9 Tripeptidyl-peptidase 2 TPP2 13
P53396 ATP-citrate synthase ACLY 13
C9J0K6 Sorcin SRI 12
P04406 Glyceraldehyde-3-phosphate dehydrogenase GAPDH 12
P07738 Bisphosphoglycerate mutase BPGM 12
B7Z3I9 Delta-aminolevulinic acid dehydratase ALAD 12
Q86X55 Histone-arginine methyltransferase CARM1 CARM1 12
P07195 L-lactate dehydrogenase B chain;L-lactate dehydrogenase LDHB 12
P23526 Adenosylhomocysteinase AHCY 12
Q32Q12 Nucleoside diphosphate kinase NME1-NME2 12
B7Z7A9 Phosphoglycerate kinase 1 PGK1 11
P11166 Solute carrier family 2, facilitated glucose transporter member 1 SLC2A1 11
P22303 Acetylcholinesterase ACHE 11
Q9NP58 ATP-binding cassette sub-family B member 6, mitochondrial ABCB6 11
P40925 Malate dehydrogenase, cytoplasmic;Malate dehydrogenase MDH1 11
P00352 Retinal dehydrogenase 1 ALDH1A1 11
F2Z2V0 Copine-1 CPNE1 11
K7EMC9 WW domain-binding protein 2 WBP2 10
F5H7S3 Tropomyosin alpha-1 chain TPM1 10
A6NN80 Annexin A6;Annexin ANXA6 10
P30043 Flavin reductase (NADPH) BLVRB 9
H7BXD5 Grancalcin GCA 9
P04083 Annexin A1;Annexin ANXA1 9
P62937 Peptidyl-prolyl cis-trans isomerase PPIA 9
P37837 Transaldolase TALDO1 9
Q06830 Peroxiredoxin-1 PRDX1 9
O75131 Copine-3 CPNE3 9
P00390 Glutathione reductase, mitochondrial GSR 9
E7EQB2 Lactotransferrin LTF 9
P07384 Calpain-1 catalytic subunit CAPN1 9
P02042 Hemoglobin subunit delta HBD 8
P30086 Phosphatidylethanolamine-binding protein 1;Hippocampal cholinergic neurostimulating peptide PEBP1 8
P35613 Basigin BSG 8
Q9H0U4 Ras-related protein Rab-1B;Putative Ras-related protein Rab-1C RAB1B;RAB1C 8
P63092 Guanine nucleotide-binding protein G(s) subunit alpha isoforms GNAS 8
P48506 Glutamate--cysteine ligase catalytic subunit GCLC 8
P06702 Protein S100-A9 S100A9 7
Q9UBV8 Peflin PEF1 7
P17931 Galectin-3;Galectin LGALS3 7
P28066 Proteasome subunit alpha type-5 PSMA5 7
P07451 Carbonic anhydrase 3 CA3 7
E7EQ12 Calpastatin CAST 7
P50895 Basal cell adhesion molecule BCAM 7
P28074 Proteasome subunit beta type-5 PSMB5 7
G3V5Z7 Proteasome subunit alpha type;Proteasome subunit alpha type-6 PSMA6 7
P25786 Proteasome subunit alpha type-1 PSMA1 7
G3V1D3 Dipeptidyl peptidase 3 DPP3 7
P49247 Ribose-5-phosphate isomerase RPIA 7
Q5T9B7 Adenylate kinase isoenzyme 1 AK1 7
P25789 Proteasome subunit alpha type-4; Proteasome subunit beta type PSMA4 7
B4E022 Transketolase TKT 7
J3QS39
Ubiquitin-60S ribosomal protein L40;Ubiquitin;60S ribosomal protein L40;Ubiquitin-40S 
ribosomal protein S27a;Ubiquitin;40S ribosomal protein S27a;Polyubiquitin-
B;Ubiquitin;Polyubiquitin-C;Ubiquitin
UBB;RPS27A
;UBC;UBA52;
UBBP4
6
H0Y7A7 Calmodulin CALM2 6
P28070 Proteasome subunit beta type-4 PSMB4 6
Q9H4G4 Golgi-associated plant pathogenesis-related protein 1 GLIPR2 6
Q9BY43 Charged multivesicular body protein 4a CHMP4A 6
P48426 Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha PIP4K2A 6
P28289 Tropomodulin-1 TMOD1 6
P07911 Uromodulin;Uromodulin, secreted form UMOD 6
Q9GZP4 PITH domain-containing protein 1 PITHD1 6
P78417 Glutathione S-transferase omega-1 GSTO1 6
P25788 Proteasome subunit alpha type-3 PSMA3 6
O14818 Proteasome subunit alpha type-7;Proteasome subunit alpha type-7-like PSMA7;PSMA8 6
P08107 Heat shock 70 kDa protein 1A/1B HSPA1A 6
H0YD13 CD44 antigen CD44 6
P61225 Ras-related protein Rap-2b;Ras-related protein Rap-2c;Ras-related protein Rap-2a RAP2B;RAP2A;RAP2C 6
P05109 Protein S100-A8;Protein S100-A8, N-terminally processed S100A8 6
P23528 Cofilin-1 CFL1 6
Q99808 Equilibrative nucleoside transporter 1 SLC29A1 6
P84077 ADP-ribosylation factor 1;ADP-ribosylation factor 3;ADP-ribosylation factor 5;ADP-ribosylation factor 4
ARF1;ARF3;A
RF5;ARF4 6
P31946 14-3-3 protein beta/alpha;14-3-3 protein beta/alpha, N-terminally processed YWHAB 6
C9JIS1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2;Guanine nucleotide-binding protein subunit beta-4 GNB2;GNB4 6
P53990 IST1 homolog IST1 6
Q99497 Protein DJ-1 PARK7 6
F5H7U0 6-phosphogluconate dehydrogenase, decarboxylating PGD 6
B7Z7E9 Aspartate aminotransferase, cytoplasmic GOT1 6
P62834 Ras-related protein Rap-1A;Ras-related protein Rap-1b;Ras-related protein Rap-1b-like protein
RAP1A;RAP1
B 6
P04899 Guanine nucleotide-binding protein G(i) subunit alpha-2 GNAI2 6
P25325 3-mercaptopyruvate sulfurtransferase;Sulfurtransferase MPST 6
Q9NP79 Vacuolar protein sorting-associated protein VTA1 homolog VTA1 6
P00492 Hypoxanthine-guanine phosphoribosyltransferase HPRT1 6
Q16531 DNA damage-binding protein 1 DDB1 6
P22314 Ubiquitin-like modifier-activating enzyme 1 UBA1 6
P00441 Superoxide dismutase [Cu-Zn] SOD1 5
H7BY58 Protein-L-isoaspartate O-methyltransferase;Protein-L-isoaspartate(D-aspartate) O-methyltransferase PCMT1 5
P10768 S-formylglutathione hydrolase ESD 5
P09543 2,3-cyclic-nucleotide 3-phosphodiesterase CNP 5
P06733 Alpha-enolase;Enolase ENO1 5
P26038 Moesin MSN 5
O75368 SH3 domain-binding glutamic acid-rich-like protein SH3BGRL 5
K7EQ48 Glucose-6-phosphate isomerase GPI 5
P25787 Proteasome subunit alpha type-2 PSMA2 5
P49721 Proteasome subunit beta type-2 PSMB2 5
F5H8J2 Protein disulfide-isomerase P4HB 5
C9J9P4 Phospholipid scramblase 1 PLSCR1 5
P09211 Glutathione S-transferase P GSTP1 5
B5MDF5 GTP-binding nuclear protein Ran RAN 5
P07900 Heat shock protein HSP 90-alpha HSP90AA1 5
K7EQ02 DAZ-associated protein 1 DAZAP1 5
Q13630 GDP-L-fucose synthase TSTA3 5
F5H0T1 Stress-induced-phosphoprotein 1 STIP1 5
P50502 Hsc70-interacting protein;Putative protein FAM10A5;Putative protein FAM10A4 ST13;ST13P5;ST13P4 5
P20618 Proteasome subunit beta type-1 PSMB1 5
P62805 Histone H4 HIST1H4A 5
P51148 Ras-related protein Rab-5C RAB5C 5
H7C2G2 Ecto-ADP-ribosyltransferase 4 ART4 5
J3KQ18 D-dopachrome decarboxylase;D-dopachrome decarboxylase-like protein DDT;DDTL 5
H3BPK3 Hydroxyacylglutathione hydrolase, mitochondrial HAGH 5
B4DIT7 Protein-glutamine gamma-glutamyltransferase 2 TGM2 5
O43633 Charged multivesicular body protein 2a CHMP2A 5
B4DQH4 T-complex protein 1 subunit theta CCT8 5
Q9UN37 Vacuolar protein sorting-associated protein 4A VPS4A 5
I3L397 Eukaryotic translation initiation factor 5A-1;Eukaryotic translation initiation factor 5A-1-like EIF5A;EIF5AL1 5
Q9Y5Z4 Heme-binding protein 2 HEBP2 5
Q9UKV8 Protein argonaute-2 AGO2 5
F5H442 Tumor susceptibility gene 101 protein TSG101 5
H3BLV0 Complement decay-accelerating factor CD55 5
P02008 Hemoglobin subunit zeta HBZ 5
E7EPV7 Alpha-synuclein SNCA 4
P63104 14-3-3 protein zeta/delta YWHAZ 4
P02724 Glycophorin-A GYPA;GPErik 4
U3KQE2 Calpain small subunit 1 CAPNS1 4
Q9NP59 Solute carrier family 40 member 1 SLC40A1 4
Q5QPM9 Proteasome inhibitor PI31 subunit PSMF1 4
C9J8U2 Nicotinate phosphoribosyltransferase NAPRT 4
P61981 14-3-3 protein gamma;14-3-3 protein gamma, N-terminally processed YWHAG 4
Q9UQ80 Proliferation-associated protein 2G4 PA2G4 4
E5RJR5 S-phase kinase-associated protein 1 SKP1 4
Q9NRV9 Heme-binding protein 1 HEBP1 4
Q9H444 Charged multivesicular body protein 4b CHMP4B 4
P10599 Thioredoxin TXN 4
Q5VSJ9 Blood group Rh(CE) polypeptide;Blood group Rh(D) polypeptide RHCE;RHD 4
Q9UK41 Vacuolar protein sorting-associated protein 28 homolog VPS28 4
Q9Y3I1 F-box only protein 7 FBXO7 4
P61026 Ras-related protein Rab-10 RAB10 4
Q14974 Importin subunit beta-1 KPNB1 4
P27797 Calreticulin CALR 4
P18669 Phosphoglycerate mutase 1;Probable phosphoglycerate mutase 4 PGAM1;PGAM4 4
P54725 UV excision repair protein RAD23 homolog A RAD23A 4
P30613 Pyruvate kinase PKLR PKLR 4
P63000 Ras-related C3 botulinum toxin substrate 1;Ras-related C3 botulinum toxin substrate 3;Ras-related C3 botulinum toxin substrate 2
RAC1;RAC3;
RAC2 4
P05164 Myeloperoxidase MPO 4
F5GWY2 Bifunctional purine biosynthesis protein PURH;Phosphoribosylaminoimidazolecarboxamide formyltransferase;IMP cyclohydrolase ATIC 4
P48637 Glutathione synthetase GSS 4
F5H5V4 26S proteasome non-ATPase regulatory subunit 9 PSMD9 4
G5E9R5 Low molecular weight phosphotyrosine protein phosphatase ACP1 3
P46976 Glycogenin-1 GYG1 3
P28072 Proteasome subunit beta type-6 PSMB6 3
P26447 Protein S100-A4 S100A4 3
F5GXQ0 BRO1 domain-containing protein BROX BROX 3
P08754 Guanine nucleotide-binding protein G(k) subunit alpha GNAI3 3
Q99436 Proteasome subunit beta type-7 PSMB7 3
P62942 Peptidyl-prolyl cis-trans isomerase FKBP1A 3
U3KQK0 Histone H2B HIST1H2B 3
J3QKR3 Proteasome subunit beta type-3 PSMB3 3
P01116 GTPase KRas;GTPase KRas, N-terminally processed;GTPase HRas;GTPase HRas, N-terminally processed;GTPase NRas
KRAS;HRAS;
NRAS 3
P13489 Ribonuclease inhibitor RNH1 3
Q08722 Leukocyte surface antigen CD47 CD47 3
Q5T123 SH3 domain-binding glutamic acid-rich-like protein 3 SH3BGRL3 3
Q8WYQ7 Galectin;Galectin-9 LGALS9 3
O75695 Protein XRP2 RP2 3
P00167 Cytochrome b5 CYB5A 3
Q9Y4D1 Disheveled-associated activator of morphogenesis 1 DAAM1 3
P11021 78 kDa glucose-regulated protein HSPA5 3
H7C1D4 Translin TSN 3
P07737 Profilin-1 PFN1 3
M0R389 Platelet-activating factor acetylhydrolase IB subunit gamma PAFAH1B3 3
A6NJA2 Ubiquitin carboxyl-terminal hydrolase 14 USP14 3
P10644 cAMP-dependent protein kinase type I-alpha regulatory subunit PRKAR1A 3
Q9BS40 Latexin LXN 3
G5EA52 Protein disulfide-isomerase A3 PDIA3 3
P53004 Biliverdin reductase A BLVRA 3
Q04656 Copper-transporting ATPase 1 ATP7A 3
H9KV70 Neutrophil gelatinase-associated lipocalin LCN2 3
O00299 Chloride intracellular channel protein 1 CLIC1 3
F8WF69 Clathrin light chain A CLTA 3
G3V2F7 Ubiquitin-conjugating enzyme E2 variant 1;Ubiquitin-conjugating enzyme E2 variant 2 UBE2V1;UBE2V2 3
F8WDS9 LanC-like protein 1 LANCL1 3
P60891 Ribose-phosphate pyrophosphokinase 1 PRPS1 3
K7ESE8 Bleomycin hydrolase BLMH 3
H0YNE3 Proteasome activator complex subunit 1 PSME1 3
P16930 Fumarylacetoacetase FAH 3
F8VSD4 Ubiquitin-conjugating enzyme E2 N UBE2N 3
P07203 Glutathione peroxidase 1 GPX1 3
P62328 Thymosin beta-4;Hematopoietic system regulatory peptide TMSB4X;TMSB4XP4 3
E5RIW3 Tubulin-specific chaperone A TBCA 3
M0R0Y2 Alpha-soluble NSF attachment protein NAPA 3
P15374 Ubiquitin carboxyl-terminal hydrolase isozyme L3 UCHL3 3
P04921 Glycophorin-C GYPC 2
H0YDI1 Lymphocyte function-associated antigen 3 CD58 2
B4E220 Aquaporin-1 AQP1 2
C9JEN3 Protein lifeguard 3 TMBIM1 2
F5H2R5 Rho GDP-dissociation inhibitor 2 ARHGDIB 2
Q53TN4 Cytochrome b reductase 1 CYBRD1 2
Q9NZD4 Alpha-hemoglobin-stabilizing protein AHSP 2
Q8NHG7 Small VCP/p97-interacting protein SVIP 2
Q5JYX0 Cell division control protein 42 homolog CDC42 2
Q71RC9 Small integral membrane protein 5 SMIM5 2
E9PNW4 CD59 glycoprotein CD59 2
P09105 Hemoglobin subunit theta-1 HBQ1 2
R4GN98 Protein S100;Protein S100-A6 S100A6 2
O75531 Barrier-to-autointegration factor;Barrier-to-autointegration factor, N-terminally processed BANF1 2
Q5T6W5 Heterogeneous nuclear ribonucleoprotein K HNRNPK 2
F5H4Q5 Vacuolar protein sorting-associated protein 37C VPS37C 2
J3QK90 NSFL1 cofactor p47 NSFL1C 2
H3BV85 BolA-like protein 2 BOLA2B;BOLA2 2
Q9NRX4 14 kDa phosphohistidine phosphatase PHPT1 2
H3BS66 Small integral membrane protein 1 SMIM1 2
E7ESC6 Exportin-7 XPO7 2
P68402 Platelet-activating factor acetylhydrolase IB subunit beta PAFAH1B2 2
Q9BRF8 Serine/threonine-protein phosphatase CPPED1 CPPED1 2
P08246 Neutrophil elastase ELANE 2
E9PN50 26S protease regulatory subunit 6A PSMC3 2
E7EUC7 UTP--glucose-1-phosphate uridylyltransferase UGP2 2
B8ZZB8 CB1 cannabinoid receptor-interacting protein 1 CNRIP1 2
E9PCS3 26S proteasome non-ATPase regulatory subunit 2 PSMD2 2
P59666 Neutrophil defensin 3;HP 3-56;Neutrophil defensin 2;Neutrophil defensin 1;HP 1-56;Neutrophil defensin 2
DEFA3;DEFA
1 2
O15400 Syntaxin-7 STX7 2
P00338 L-lactate dehydrogenase A chain LDHA 2
P61970 Nuclear transport factor 2 NUTF2 2
E7EMV0 Protein diaphanous homolog 1 DIAPH1 2
F5GY90 Porphobilinogen deaminase HMBS 2
P61020 Ras-related protein Rab-5B RAB5B 2
Q99828 Calcium and integrin-binding protein 1 CIB1 2
B4DUA0 Plastin-2 LCP1 2
C9JTY3 Protein TFG TFG 2
P27348 14-3-3 protein theta YWHAQ 2
H0YKZ7 Annexin;Annexin A2;Putative annexin A2-like protein ANXA2;ANXA2P2 2
P08238 Heat shock protein HSP 90-beta HSP90AB1 2
J3KQP6 Ras-related protein Rab-11B;Ras-related protein Rab-11A RAB11A;RAB11B 2
A6NMU3 Signal transducing adapter molecule 1 STAM 2
P53985 Monocarboxylate transporter 1 SLC16A1 2
F6USW4 F-actin-capping protein subunit beta CAPZB 2
O14964 Hepatocyte growth factor-regulated tyrosine kinase substrate HGS 2
P20020 Plasma membrane calcium-transporting ATPase 1;Calcium-transporting ATPase ATP2B1 2
P36959 GMP reductase 1 GMPR 2
Q9Y376 Calcium-binding protein 39 CAB39 2
Q9Y6M5 Zinc transporter 1 SLC30A1 2
Q8IZ83 Aldehyde dehydrogenase family 16 member A1 ALDH16A1 2
Q99459 Cell division cycle 5-like protein CDC5L 2
P06132 Uroporphyrinogen decarboxylase UROD 2
J3KNT0 Fascin FSCN1 2
P49189 4-trimethylaminobutyraldehyde dehydrogenase ALDH9A1 2
H3BNT7 26S proteasome non-ATPase regulatory subunit 7 PSMD7 2
P05023
Sodium/potassium-transporting ATPase subunit alpha-1;Sodium/potassium-transporting 
ATPase subunit alpha-3;Sodium/potassium-transporting ATPase subunit alpha-
2;Sodium/potassium-transporting ATPase subunit alpha-4;Potassium-transporting ATPase 
alpha chain 1;Potassium-transporting ATPase alpha chain 2
ATP1A1;ATP
1A2;ATP1A3;
ATP1A4;ATP
4A;ATP12A
2
P34932 Heat shock 70 kDa protein 4 HSPA4 2
K7EMV3 Histone H3 H3F3B 2
Q8IU68 Transmembrane channel-like protein 8 TMC8 2
E7ENZ3 T-complex protein 1 subunit epsilon CCT5 2
Q5TZA2 Rootletin CROCC 2
Q9P203 BTB/POZ domain-containing protein 7 BTBD7 2
Q7LBR1 Charged multivesicular body protein 1b CHMP1B 2
U3KQ56 Glyoxylate reductase/hydroxypyruvate reductase GRHPR 2
H0YJ11 Alpha-actinin-1;Alpha-actinin-2;Alpha-actinin-4 ACTN1;ACTN4;ACTN2 2
Q9UDT6 CAP-Gly domain-containing linker protein 2 CLIP2 2
P09960 Leukotriene A-4 hydrolase LTA4H 2
Q5HY54 Filamin-A FLNA 2
E9PJL5 Uncharacterized protein C12orf55;Putative uncharacterized protein C12orf63 C12orf55;C12orf63 2
G3V2U7 Acylphosphatase;Acylphosphatase-1 FBN3;ACYP1 2
E9PQN4 Complement receptor type 1 CR1 2
Q9BSL1 Ubiquitin-associated domain-containing protein 1 UBAC1 2
Q04917 14-3-3 protein eta YWHAH 2
B7ZBP9 Serine/threonine-protein phosphatase 2A activator
PPP2R4;DKF
Zp781M1716
5
2
Q8NDC0 MAPK-interacting and spindle-stabilizing protein-like MAPK1IP1L 1
P68133 Actin, alpha skeletal muscle;Actin, alpha cardiac muscle 1;Actin, gamma-enteric smooth muscle;Actin, aortic smooth muscle
ACTA1;ACTC
1;ACTG2;AC
TA2
1
P69891 Hemoglobin subunit gamma-1 HBG1 1
S4R3Y4 Protein AMBP;Alpha-1-microglobulin;Inter-alpha-trypsin inhibitor light chain;Trypstatin AMBP 1
I3L3E4 Charged multivesicular body protein 6 CHMP6 1
Q16570 Atypical chemokine receptor 1 ACKR1 1
Q5VY30 Retinol-binding protein 4;Plasma retinol-binding protein(1-182);Plasma retinol-binding protein(1-181);Plasma retinol-binding protein(1-179);Plasma retinol-binding protein(1-176) RBP4 1
E7END7 Ras-related protein Rab-1A RAB1A 1
Q5VU59 TPM3 1
P17066 Heat shock 70 kDa protein 6;Putative heat shock 70 kDa protein 7 HSPA6;HSPA7 1
Q04760 Lactoylglutathione lyase GLO1 1
D6RD66 WD repeat-containing protein 1 WDR1 1
K7EM02 Katanin p60 ATPase-containing subunit A-like 2 KATNAL2 1
P14209 CD99 antigen CD99 1
E9PIR7 Thioredoxin reductase 1, cytoplasmic GML;TXNRD1 1
K7EMQ9 EIF3K 1
P15531 Nucleoside diphosphate kinase A NME1 1
H7BZT4 Small ubiquitin-related modifier 4;Small ubiquitin-related modifier 2;Small ubiquitin-related modifier 3
SUMO2;SUM
O3;SUMO4 1
O00560 Syntenin-1 SDCBP 1
Q9BVM4 Gamma-glutamylaminecyclotransferase GGACT 1
K7EKH5 Fructose-bisphosphate aldolase C ALDOC 1
P49773 Histidine triad nucleotide-binding protein 1 HINT1 1
H0YBY6 Disks large-associated protein 2 DLGAP2 1
Q9Y624 Junctional adhesion molecule A F11R 1
B1AKQ8 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1;Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 GNB1;GNB3 1
K7EKN6 Urea transporter 1 SLC14A1 1
I3L0K2 Thioredoxin domain-containing protein 17 TXNDC17 1
A8MXY0 Syntaxin-4 STX4 1
O14773 Tripeptidyl-peptidase 1 TPP1 1
E9PNW0 Nucleosome assembly protein 1-like 1;Nucleosome assembly protein 1-like 4 NAP1L4;NAP1L1 1
Q5TDH0 Protein DDI1 homolog 2 DDI2 1
Q96JM4 Leucine-rich repeat and IQ domain-containing protein 1 LRRIQ1 1
F5GWT9 Phosphoribosylformylglycinamidine synthase PFAS 1
F2Z3J2 26S proteasome non-ATPase regulatory subunit 5 PSMD5 1
J3QL74 Zinc finger and BTB domain-containing protein 14 ZBTB14 1
E9PJC7 CD82 antigen CD82 1
Q9H936 Mitochondrial glutamate carrier 1 SLC25A22 1
D6RD63 COP9 signalosome complex subunit 4 COPS4 1
Q6B0K9 Hemoglobin subunit mu HBM 1
Q31611 HLA class I histocompatibility antigen, alpha chain G HLA-G 1
H7BY04 Laminin subunit gamma-3 LAMC3 1
Q9UL25 Ras-related protein Rab-21 RAB21 1
H7C3P7 Ras-related protein Ral-A RALA 1
P08311 Cathepsin G CTSG 1
E9PE37 Ras-related protein Rab-2A;Ras-related protein Rab-2B RAB2B;RAB2A 1
G3V1N2 HBA2 1
P00387 NADH-cytochrome b5 reductase 3;NADH-cytochrome b5 reductase 3 membrane-bound form;NADH-cytochrome b5 reductase 3 soluble form CYB5R3 1
O75339 Cartilage intermediate layer protein 1;Cartilage intermediate layer protein 1 C1;Cartilage intermediate layer protein 1 C2 CILP 1
P14324 Farnesyl pyrophosphate synthase FDPS 1
K7EKG2 Thioredoxin-like protein 1 TXNL1 1
B. Uniprot Complete Proteome Homo sapiens database when the heamoglobin was analyzed 
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P02549 Spectrin alpha chain, erythrocytic 1 SPTA1 197
P11277 Spectrin beta chain, erythrocytic SPTB 177
P16157 Ankyrin-1 ANK1 94
P55072 Transitional endoplasmic reticulum ATPase VCP 53
P111714 Protein 4.1 EPB41 52
P35579 Myosin-9 MYH9 44
Q8WUM4 Programmed cell death 6-interacting protein PDCD6IP 43
P02730 Band 3 anion transport protein SLC4A1 43
P16452 Erythrocyte membrane protein band 4.2 EPB42 42
P04040 Catalase CAT 40
A0A087WVQ
6 Clathrin heavy chain;Clathrin heavy chain 1 CLTC 38
P35612 Beta-adducin ADD2 37
P16157 Ankyrin-1 ANK1 36
Q14254 Flotillin-2 FLOT2 33
P20073 Annexin A7 ANXA7 31
O75955 Flotillin-1 FLOT1 30
P53396 ATP-citrate synthase ACLY 30
P06753 TPM3 29
P49368 T-complex protein 1 subunit gamma CCT3 29
P236344 Plasma membrane calcium-transporting ATPase 4 ATP2B4 28
P11142 Heat shock cognate 71 kDa protein HSPA8 28
P60709 Actin, cytoplasmic 1;Actin, cytoplasmic 1, N-terminally processed ACTB 28
Q5T4S7 E3 ubiquitin-protein ligase UBR4 UBR4 27
P78371 T-complex protein 1 subunit beta CCT2 26
P28289 Tropomodulin-1 TMOD1 26
P50395 Rab GDP dissociation inhibitor beta GDI2 25
P27105 Erythrocyte band 7 integral membrane protein STOM 25
P68871 Hemoglobin subunit beta;LVV-hemorphin-7;Spinorphin HBB 25
P02730 Band 3 anion transport protein SLC4A1 25
Q00013 55 kDa erythrocyte membrane protein MPP1 24
J3KPS3 Fructose-bisphosphate aldolase;Fructose-bisphosphate aldolase A ALDOA 24
P00352 Retinal dehydrogenase 1 ALDH1A1 24
Q86VP6 Cullin-associated NEDD8-dissociated protein 1 CAND1 24
P49327 Fatty acid synthase FASN 24
Q13228 Selenium-binding protein 1 SELENBP1 22
P00915 Carbonic anhydrase 1 CA1 22
P50991 T-complex protein 1 subunit delta CCT4 22
P50990 T-complex protein 1 subunit theta CCT8 22
P32119 Peroxiredoxin-2 PRDX2 21
P50995 Annexin A11 ANXA11 21
P69905 Hemoglobin subunit alpha HBA1 21
P00558 Phosphoglycerate kinase 1 PGK1 20
H7BXK9 ATP-binding cassette sub-family B member 6, mitochondrial ABCB6 20
P08758 Annexin A5;Annexin ANXA5 20
P09525 Annexin A4;Annexin ANXA4 20
P07900 Heat shock protein HSP 90-alpha HSP90AA1 20
P48643 T-complex protein 1 subunit epsilon CCT5 20
P07384 Calpain-1 catalytic subunit CAPN1 20
P22314 Ubiquitin-like modifier-activating enzyme 1 UBA1 19
P04406 Glyceraldehyde-3-phosphate dehydrogenase GAPDH 19
Q08495 Dematin DMTN 19
Q99832 T-complex protein 1 subunit eta CCT7 19
P29144 Tripeptidyl-peptidase 2 TPP2 19
P30041 Peroxiredoxin-6 PRDX6 18
E9PM69 26S protease regulatory subunit 6A PSMC3 18
P40227 T-complex protein 1 subunit zeta CCT6A 18
P50570 Dynamin-2 DNM2 18
E7EQB2 Lactotransferrin;Lactoferricin-H;Kaliocin-1;Lactoferroxin-A;Lactoferroxin-B;Lactoferroxin-C LTF 18
P31948 Stress-induced-phosphoprotein 1 STIP1 18
E7ESC6 Exportin-7 XPO7 18
E7EV99 Alpha-adducin ADD1 17
P62258 14-3-3 protein epsilon YWHAE 17
P30613 Pyruvate kinase PKLR PKLR 17
A0A0G2JIW1 Heat shock 70 kDa protein 1B;Heat shock 70 kDa protein 1A HSPA1B;HSPA1A 17
Q16531 DNA damage-binding protein 1 DDB1 17
P11021 78 kDa glucose-regulated protein HSPA5 17
F5H2F4 C-1-tetrahydrofolate synthase, cytoplasmic;Methylenetetrahydrofolate dehydrogenase MTHFD1 17
P07195 L-lactate dehydrogenase B chain;L-lactate dehydrogenase LDHB 16
P45974 Ubiquitin carboxyl-terminal hydrolase 5 USP5 16
O43242 26S proteasome non-ATPase regulatory subunit 3 PSMD3 16
C9J0K6 Sorcin SRI 16
P08133 Annexin A6;Annexin ANXA6 16
Q13200 26S proteasome non-ATPase regulatory subunit 2 PSMD2 16
P23276 Kell blood group glycoprotein KEL 16
P34932 Heat shock 70 kDa protein 4 HSPA4 16
A0A0A0MSI0 Peroxiredoxin-1 PRDX1 16
Q9Y230 RuvB-like 2 RUVBL2 16
Q5XPI4 E3 ubiquitin-protein ligase RNF123 RNF123 16
P68871 Hemoglobin subunit beta;LVV-hemorphin-7;Spinorphin HBB 15
P60174 Triosephosphate isomerase TPI1 15
P00491 Purine nucleoside phosphorylase PNP 15
C9JIF9 Acylamino-acid-releasing enzyme APEH 15
H7BYY1 Tropomyosin alpha-1 chain TPM1 15
P35998 26S protease regulatory subunit 7 PSMC2 15
P17987 T-complex protein 1 subunit alpha TCP1 15
P09543 2,3-cyclic-nucleotide 3-phosphodiesterase CNP 15
Q99460 26S proteasome non-ATPase regulatory subunit 1 PSMD1 15
Q9Y4E8 Ubiquitin carboxyl-terminal hydrolase 15 USP15 15
Q9C0C9 E2/E3 hybrid ubiquitin-protein ligase UBE2O UBE2O 15
P26038 Moesin MSN 15
P04083 Annexin A1;Annexin ANXA1 14
P30043 Flavin reductase (NADPH) BLVRB 14
P11166 Solute carrier family 2, facilitated glucose transporter member 1 SLC2A1 14
P00918 Carbonic anhydrase 2 CA2 14
P06733 Alpha-enolase ENO1 14
Q5TDH0 Protein DDI1 homolog 2 DDI2 14
B0QZ18 Copine-1 CPNE1 14
O75326 Semaphorin-7A SEMA7A 14
P05164 Myeloperoxidase MPO 14
Q9Y265 RuvB-like 1 RUVBL1 14
P29401 Transketolase TKT 14
I3L0N3 Vesicle-fusing ATPase NSF 14
Q4VB86 Protein 4.1 EPB41 14
P11277 Spectrin beta chain, erythrocytic SPTB 14
P13716 Delta-aminolevulinic acid dehydratase ALAD 13
P07738 Bisphosphoglycerate mutase BPGM 13
P48506 Glutamate--cysteine ligase catalytic subunit GCLC 13
Q99816 Tumor susceptibility gene 101 protein TSG101 13
O14818 Proteasome subunit alpha type-7 PSMA7 13
P23526 Adenosylhomocysteinase AHCY 13
P61225 Ras-related protein Rap-2b RAP2B 13
O00231 26S proteasome non-ATPase regulatory subunit 11 PSMD11 13
P11413 Glucose-6-phosphate 1-dehydrogenase G6PD 13
P00338 L-lactate dehydrogenase A chain LDHA 12
Q99808 Equilibrative nucleoside transporter 1 SLC29A1 12
A6NJA2 Ubiquitin carboxyl-terminal hydrolase;Ubiquitin carboxyl-terminal hydrolase 14 USP14 12
Q06323 Proteasome activator complex subunit 1 PSME1 12
P28074 Proteasome subunit beta type-5 PSMB5 12
B3KQV6 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform PPP2R1A 12
Q14974 Importin subunit beta-1 KPNB1 12
P25786 Proteasome subunit alpha type-1;Proteasome subunit alpha type PSMA1 12
Q86X55 Histone-arginine methyltransferase CARM1 CARM1 12
A6NG10 WW domain-binding protein 2 WBP2 12
P63092 Guanine nucleotide-binding protein G(s) subunit alpha GNAS 12
P31939 Bifunctional purine biosynthesis protein PURH;Phosphoribosylaminoimidazolecarboxamide formyltransferase;IMP cyclohydrolase ATIC 12
P52209 6-phosphogluconate dehydrogenase, decarboxylating PGD 12
A0A087X0C8 Calpain-5 CAPN5 12
F8W9S7 GTPase-activating protein and VPS9 domain-containing protein 1 GAPVD1 12
P60842 Eukaryotic initiation factor 4A-I EIF4A1 12
P69905 Hemoglobin subunit alpha HBA1 11
Q6XQN6 Nicotinate phosphoribosyltransferase NAPRT 11
P48637 Glutathione synthetase GSS 11
H7BZ94 Protein disulfide-isomerase P4HB 11
P21980 Protein-glutamine gamma-glutamyltransferase 2 TGM2 11
P50895 Basal cell adhesion molecule BCAM 11
A0A087X2I1 26S protease regulatory subunit 10B PSMC6 11
G3V1D3 Dipeptidyl peptidase 3 DPP3 11
P05023 Sodium/potassium-transporting ATPase subunit alpha-1;Sodium/potassium-transporting ATPase subunit alpha-3
ATP1A1;ATP
1A3 11
P40925 Malate dehydrogenase, cytoplasmic;Malate dehydrogenase MDH1 11
Q9UKV8 Protein argonaute-2 AGO2 11
P30566 Adenylosuccinate lyase ADSL 11
P20618 Proteasome subunit beta type-1 PSMB1 11
P17858 ATP-dependent 6-phosphofructokinase, liver type PFKL 11
A0A087X253 AP-2 complex subunit beta AP2B1 11
O95782 AP-2 complex subunit alpha-1 AP2A1 11
O00232 26S proteasome non-ATPase regulatory subunit 12 PSMD12 11
Q9BSL1 Ubiquitin-associated domain-containing protein 1 UBAC1 11
A0A087WUL
0
Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (cyclizing);ATP-
dependent dihydroxyacetone kinase;FAD-AMP lyase (cyclizing) TKFC;DAK 11
P69891 Hemoglobin subunit gamma-1 HBG1 11
A0A087WZE
4 Spectrin alpha chain, erythrocytic 1 SPTA1 11
P48426 Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha PIP4K2A 10
P10644 cAMP-dependent protein kinase type I-alpha regulatory subunit PRKAR1A 10
Q9BWD1 Acetyl-CoA acetyltransferase, cytosolic ACAT2 10
P62191 26S protease regulatory subunit 4 PSMC1 10
E9PBS1 Multifunctional protein ADE2;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole carboxylase PAICS 10
M0R0Y2 Alpha-soluble NSF attachment protein NAPA 10
P78417 Glutathione S-transferase omega-1 GSTO1 10
P25789 Proteasome subunit alpha type-4;Proteasome subunit alpha type;Proteasome subunit beta type PSMA4 10
Q9H0U4 Ras-related protein Rab-1B;Putative Ras-related protein Rab-1C RAB1B;RAB1C 10
Q16401 26S proteasome non-ATPase regulatory subunit 5 PSMD5 10
P30101 Protein disulfide-isomerase A3 PDIA3 10
D6RAX7 COP9 signalosome complex subunit 4 COPS4 10
O75340 Programmed cell death protein 6 PDCD6 10
Q96P70 Importin-9 IPO9 10
P38606 V-type proton ATPase catalytic subunit A ATP6V1A 10
A0A0G2JH68 Protein diaphanous homolog 1 DIAPH1 10
Q5T9B7 Adenylate kinase isoenzyme 1 AK1 10
O14980 Exportin-1 XPO1 10
P43686 26S protease regulatory subunit 6B PSMC4 10
H0YH81 ATP synthase subunit beta;ATP synthase subunit beta, mitochondrial ATP5B 10
Q04656 Copper-transporting ATPase 1 ATP7A 10
P16452 Erythrocyte membrane protein band 4.2 EPB42 10
Q9BY43 Charged multivesicular body protein 4a CHMP4A 9
P51148 Ras-related protein Rab-5C RAB5C 9
Q9NRV9 Heme-binding protein 1 HEBP1 9
Q9UNZ2 NSFL1 cofactor p47 NSFL1C 9
Q16851 UTP--glucose-1-phosphate uridylyltransferase UGP2 9
P28066 Proteasome subunit alpha type-5 PSMA5 9
A0A0C4DGQ
5 Calpain small subunit 1 CAPNS1 9
A0A087X1Z3 Proteasome activator complex subunit 2 PSME2 9
Q01518 Adenylyl cyclase-associated protein 1 CAP1 9
B1AKQ8 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 GNB1 9
O75131 Copine-3 CPNE3 9
P54725 UV excision repair protein RAD23 homolog A RAD23A 9
P11215 Integrin alpha-M ITGAM 9
Q93008 Probable ubiquitin carboxyl-terminal hydrolase FAF-X USP9X 9
Q96G03 Phosphoglucomutase-2 PGM2 9
P49721 Proteasome subunit beta type-2 PSMB2 9
Q15008 26S proteasome non-ATPase regulatory subunit 6 PSMD6 9
Q9UNQ0 ATP-binding cassette sub-family G member 2 ABCG2 9
P22303 Acetylcholinesterase;Carboxylic ester hydrolase ACHE 9
G3V5Z7 Proteasome subunit alpha type;Proteasome subunit alpha type-6 PSMA6 9
O15439 Multidrug resistance-associated protein 4 ABCC4 9
P37837 Transaldolase TALDO1 9
O14744 Protein arginine N-methyltransferase 5 PRMT5 9
P02042 Hemoglobin subunit delta HBD 9
P25788 Proteasome subunit alpha type-3 PSMA3 8
J3QS39
Ubiquitin-60S ribosomal protein L40;Ubiquitin;60S ribosomal protein L40;Ubiquitin-40S 
ribosomal protein S27a;Ubiquitin;40S ribosomal protein S27a;Polyubiquitin-
B;Ubiquitin;Polyubiquitin-C;Ubiquitin
UBB;RPS27A
;UBC;UBA52;
UBBP4
8
O94919 Endonuclease domain-containing 1 protein ENDOD1 8
P31946 14-3-3 protein beta/alpha YWHAB 8
P60891 Ribose-phosphate pyrophosphokinase 1;Ribose-phosphate pyrophosphokinase 2;Ribose-phosphate pyrophosphokinase 3
PRPS1;PRPS
2;PRPS1L1 8
P62195 26S protease regulatory subunit 8 PSMC5 8
A0A024RA52 Proteasome subunit alpha type;Proteasome subunit alpha type-2 PSMA2 8
P04899 Guanine nucleotide-binding protein G(i) subunit alpha-2 GNAI2 8
Q13561 Dynactin subunit 2 DCTN2 8
P53004 Biliverdin reductase A BLVRA 8
P00387 NADH-cytochrome b5 reductase 3 CYB5R3 8
P16152 Carbonyl reductase [NADPH] 1 CBR1 8
P06744 Glucose-6-phosphate isomerase GPI 8
Q99733 Nucleosome assembly protein 1-like 4 NAP1L4 8
P04792 Heat shock protein beta-1 HSPB1 8
P17612 cAMP-dependent protein kinase catalytic subunit alpha;cAMP-dependent protein kinase catalytic subunit beta
PRKACA;KIN
27;PRKACB 8
P20340 Ras-related protein Rab-6A RAB6A 8
P13796 Plastin-2 LCP1 8
P52907 F-actin-capping protein subunit alpha-1 CAPZA1 8
Q14697 Neutral alpha-glucosidase AB GANAB 8
P08514 Integrin alpha-IIb;Integrin alpha-IIb heavy chain;Integrin alpha-IIb light chain, form 1;Integrin alpha-IIb light chain, form 2 ITGA2B 8
P26641 Elongation factor 1-gamma EEF1G 8
Q9UQ80 Proliferation-associated protein 2G4 PA2G4 8
Q9Y4D1 Disheveled-associated activator of morphogenesis 1 DAAM1 8
P11166 Solute carrier family 2, facilitated glucose transporter member 1 SLC2A1 8
P63261
Actin, cytoplasmic 2;Actin, cytoplasmic 2, N-terminally processed;Actin, cytoplasmic 1;Actin, 
cytoplasmic 1, N-terminally processed;Actin, gamma-enteric smooth muscle;Actin, alpha 
skeletal muscle;Actin, alpha cardiac muscle 1;Actin, aortic smooth muscle
ACTG1;ACTB
;ACTG2;ACT
A1;ACTC1;A
CTA2
8
P02008 Hemoglobin subunit zeta HBZ 8
P20073 Annexin A7 ANXA7 8
P35613 Basigin BSG 7
P49720 Proteasome subunit beta type-3 PSMB3 7
P17931 Galectin-3;Galectin LGALS3 7
P63104 14-3-3 protein zeta/delta YWHAZ 7
Q9H444 Charged multivesicular body protein 4b CHMP4B 7
O43396 Thioredoxin-like protein 1 TXNL1 7
P50502 Hsc70-interacting protein;Putative protein FAM10A4;Putative protein FAM10A5 ST13;ST13P4;ST13P5 7
E7EQ12 Calpastatin CAST 7
P49189 4-trimethylaminobutyraldehyde dehydrogenase ALDH9A1 7
Q9Y3I1 F-box only protein 7 FBXO7 7
P07954 Fumarate hydratase, mitochondrial FH 7
F6S8N6 Protein-L-isoaspartate O-methyltransferase;Protein-L-isoaspartate(D-aspartate) O-methyltransferase PCMT1 7
P49247 Ribose-5-phosphate isomerase RPIA 7
P62834 Ras-related protein Rap-1A RAP1A 7
A0A087WUQ
6 Glutathione peroxidase;Glutathione peroxidase 1 GPX1 7
O60256 Phosphoribosyl pyrophosphate synthase-associated protein 2 PRPSAP2 7
Q00796 Sorbitol dehydrogenase SORD 7
O00299 Chloride intracellular channel protein 1 CLIC1 7
Q99497 Protein deglycase DJ-1 PARK7 7
P17174 Aspartate aminotransferase, cytoplasmic GOT1 7
H7BXD5 Grancalcin GCA 7
E9PGT1 Translin TSN 7
C9J7K9 Phospholipid scramblase 1 PLSCR1 7
Q13618 Cullin-3 CUL3 7
O75695 Protein XRP2 RP2 7
P09960 Leukotriene A-4 hydrolase LTA4H 7
E9PLK3 Puromycin-sensitive aminopeptidase NPEPPS 7
P00492 Hypoxanthine-guanine phosphoribosyltransferase HPRT1 7
F5H4B6 Aldehyde dehydrogenase family 16 member A1 ALDH16A1 7
D6RA82 Annexin;Annexin A3 ANXA3 7
P61106 Ras-related protein Rab-14 RAB14 7
Q16775 Hydroxyacylglutathione hydrolase, mitochondrial HAGH 7
P07355 Annexin A2;Annexin;Putative annexin A2-like protein ANXA2;ANXA2P2 7
A0A087WX0
8 Gamma-adducin ADD3 7
P08238 Heat shock protein HSP 90-beta HSP90AB1 7
Q8IZY2 ATP-binding cassette sub-family A member 7 ABCA7 7
P14780 Matrix metalloproteinase-9 MMP9 7
P12955 Xaa-Pro dipeptidase PEPD 7
P68371 Tubulin beta-4B chain;Tubulin beta-4A chain;Tubulin beta chain TUBB4B;TUBB4A;TUBB 7
O15067 Phosphoribosylformylglycinamidine synthase PFAS 7
P35241 Radixin RDX 7
O60488 Long-chain-fatty-acid--CoA ligase 4 ACSL4 7
A0A0C4DGX
4 Cullin-1 CUL1 7
P50148 Guanine nucleotide-binding protein G(q) subunit alpha GNAQ 7
Q15907 Ras-related protein Rab-11B;Ras-related protein Rab-11A RAB11B;RAB11A 7
P30086 Phosphatidylethanolamine-binding protein 1;Hippocampal cholinergic neurostimulating peptide PEBP1 6
P55036 26S proteasome non-ATPase regulatory subunit 4 PSMD4 6
P28070 Proteasome subunit beta type-4 PSMB4 6
Q9UNS2 COP9 signalosome complex subunit 3 COPS3 6
P08754 Guanine nucleotide-binding protein G(k) subunit alpha GNAI3 6
P61006 Ras-related protein Rab-8A RAB8A 6
P61019 Ras-related protein Rab-2A RAB2A 6
H0Y8C6 Importin-5 IPO5 6
Q00577 Transcriptional activator protein Pur-alpha PURA 6
P52565 Rho GDP-dissociation inhibitor 1 ARHGDIA 6
Q9Y5Z4 Heme-binding protein 2 HEBP2 6
J3KNF4 Copper chaperone for superoxide dismutase;Superoxide dismutase [Cu-Zn] CCS 6
A0A087WXS
7 ATPase ASNA1 ASNA1 6
P05089 Arginase-1 ARG1 6
O95336 6-phosphogluconolactonase PGLS 6
Q92508 Piezo-type mechanosensitive ion channel component 1 PIEZO1 6
P84077 ADP-ribosylation factor 1;ADP-ribosylation factor 3 ARF1;ARF3 6
P21281 V-type proton ATPase subunit B, brain isoform;V-type proton ATPase subunit B, kidney isoform
ATP6V1B2;A
TP6V1B1 6
P04259 Keratin, type II cytoskeletal 6B KRT6B 6
Q92905 COP9 signalosome complex subunit 5 COPS5 6
P61163 Alpha-centractin ACTR1A 6
O95373 Importin-7 IPO7 6
C9JD73 Protein phosphatase 1 regulatory subunit 7 PPP1R7 6
Q99536 Synaptic vesicle membrane protein VAT-1 homolog VAT1 6
Q86UX7 Fermitin family homolog 3 FERMT3 6
C9JFE4 COP9 signalosome complex subunit 1 GPS1 6
P36959 GMP reductase 1 GMPR 6
B5MDF5 GTP-binding nuclear protein Ran RAN 6
F5GY90 Porphobilinogen deaminase HMBS 6
E7EX90 Dynactin subunit 1 DCTN1 6
H0Y512 Adipocyte plasma membrane-associated protein APMAP 6
Q32Q12 Nucleoside diphosphate kinase;Nucleoside diphosphate kinase B;Putative nucleoside diphosphate kinase
NME1-
NME2;NME2;
NME1;NME2
P1
6
P13807 Glycogen [starch] synthase, muscle GYS1 6
K7ES02 Bleomycin hydrolase BLMH 6
P17213 Bactericidal permeability-increasing protein BPI 6
Q9UNM6 26S proteasome non-ATPase regulatory subunit 13 PSMD13 6
J3KQ32 Obg-like ATPase 1 OLA1 6
Q9Y490 Talin-1 TLN1 6
H0YD13 CD44 antigen CD44 6
P18669 Phosphoglycerate mutase 1;Phosphoglycerate mutase 2;Probable phosphoglycerate mutase 4
PGAM1;PGA
M2;PGAM4 6
P23528 Cofilin-1 CFL1 6
Q5SR44 Complement receptor type 1 CR1 6
Q99436 Proteasome subunit beta type-7 PSMB7 6
P47756 F-actin-capping protein subunit beta CAPZB 6
P30740 Leukocyte elastase inhibitor SERPINB1 6
A0A024R571 EH domain-containing protein 1 EHD1 6
P30043 Flavin reductase (NADPH) BLVRB 6
P32119 Peroxiredoxin-2 PRDX2 6
C9J0K6 Sorcin SRI 6
P27105 Erythrocyte band 7 integral membrane protein STOM 6
P84077 ADP-ribosylation factor 1;ADP-ribosylation factor 3;ADP-ribosylation factor 5;ADP-ribosylation factor 4
ARF1;ARF3;A
RF5;ARF4 6
P61981 14-3-3 protein gamma;14-3-3 protein gamma, N-terminally processed YWHAG 5
P09211 Glutathione S-transferase P GSTP1 5
P13489 Ribonuclease inhibitor RNH1 5
Q96PU5 E3 ubiquitin-protein ligase NEDD4-like NEDD4L 5
Q5SRN7 HLA class I histocompatibility antigen, A; HLA class I histocompatibility antigen, B;HLA class I histocompatibility antigen, Cw
HLA-A;HLA-
C;HLA-B 5
P02042 Hemoglobin subunit delta HBD 5
A0A087WU2
9 Glycophorin-A GYPA 5
P00390 Glutathione reductase, mitochondrial GSR 5
Q9UBV8 Peflin PEF1 5
Q8WVM8 Sec1 family domain-containing protein 1 SCFD1 5
F6TLX2 Glyoxalase domain-containing protein 4 GLOD4 5
H3BQF1 Adenine phosphoribosyltransferase APRT 5
Q07960 Rho GTPase-activating protein 1 ARHGAP1 5
F6XSS0 Blood group Rh(CE) polypeptide;Blood group Rh(D) polypeptide RHCE;RHD 5
A0A087WY5
5 Vacuolar protein sorting-associated protein VTA1 homolog VTA1 5
G5E9W8 Glycogenin-1 GYG1 5
P07451 Carbonic anhydrase 3 CA3 5
Q08722 Leukocyte surface antigen CD47 CD47 5
X6RA14 S-formylglutathione hydrolase ESD 5
Q8IUI8 Cytokine receptor-like factor 3 CRLF3 5
Q5VW32 BRO1 domain-containing protein BROX BROX 5
P61026 Ras-related protein Rab-10 RAB10 5
A0A087WWY
3 Filamin-A FLNA 5
H0YGX7 Rho GDP-dissociation inhibitor 2 ARHGDIB 5
Q92783 Signal transducing adapter molecule 1 STAM 5
Q7Z6Z7 E3 ubiquitin-protein ligase HUWE1 HUWE1 5
H0YHC3 Nucleosome assembly protein 1-like 1 NAP1L1 5
Q5QPM7 Proteasome inhibitor PI31 subunit PSMF1 5
P09104 Gamma-enolase;Enolase ENO2 5
Q5T2B5 Cullin-2 CUL2 5
Q8WW22 DnaJ homolog subfamily A member 4 DNAJA4 5
P61201 COP9 signalosome complex subunit 2 COPS2 5
X6R433 Protein-tyrosine-phosphatase;Receptor-type tyrosine-protein phosphatase C PTPRC 5
P63000 Ras-related C3 botulinum toxin substrate 1 RAC1 5
F5GXM3 IST1 homolog IST1 5
H3BLU7 Aflatoxin B1 aldehyde reductase member 2 AKR7A2 5
P25325 3-mercaptopyruvate sulfurtransferase;Sulfurtransferase MPST 5
A0A087X0K1 Calcium-binding protein 39 CAB39 5
P23381 Tryptophan--tRNA ligase, cytoplasmic;T1-TrpRS;T2-TrpRS WARS 5
P01116 GTPase KRas;GTPase KRas, N-terminally processed KRAS 5
P30040 Endoplasmic reticulum resident protein 29 ERP29 5
P05198 Eukaryotic translation initiation factor 2 subunit 1 EIF2S1 5
Q6UX06 Olfactomedin-4 OLFM4 5
Q96KP4 Cytosolic non-specific dipeptidase CNDP2 5
Q04760 Lactoylglutathione lyase GLO1 5
J3QS39
Ubiquitin-60S ribosomal protein L40;Ubiquitin;60S ribosomal protein L40;Ubiquitin-40S 
ribosomal protein S27a;Ubiquitin;40S ribosomal protein S27a;Polyubiquitin-
B;Ubiquitin;Polyubiquitin-C;Ubiquitin
UBB;RPS27A
;UBC;UBA52;
UBBP4
5
P06702 Protein S100-A9 S100A9 5
P15531 Nucleoside diphosphate kinase A;Nucleoside diphosphate kinase;Nucleoside diphosphate kinase B
NME1;NME2;
NME1-NME2 5
E7EV99 Alpha-adducin ADD1 5
P51149 Ras-related protein Rab-7a RAB7A 4
K7N7A8 Aquaporin-1 AQP1 4
P61020 Ras-related protein Rab-5B RAB5B 4
X6R4N5 Erythroid membrane-associated protein ERMAP 4
E5RJR5 S-phase kinase-associated protein 1 SKP1 4
Q9Y315 Deoxyribose-phosphate aldolase DERA 4
X6R8F3 Neutrophil gelatinase-associated lipocalin LCN2 4
O75396 Vesicle-trafficking protein SEC22b SEC22B 4
Q15102 Platelet-activating factor acetylhydrolase IB subunit gamma PAFAH1B3 4
P51665 26S proteasome non-ATPase regulatory subunit 7 PSMD7 4
Q96FZ7 Charged multivesicular body protein 6 CHMP6 4
Q9NRQ2 Phospholipid scramblase 4 PLSCR4 4
F8VWS0 60S acidic ribosomal protein P0;60S acidic ribosomal protein P0-like RPLP0;RPLP0P6 4
O14964 Hepatocyte growth factor-regulated tyrosine kinase substrate HGS 4
A0A0A0MTJ9 Neutral cholesterol ester hydrolase 1 NCEH1 4
A0A087WY8
2 Junctional adhesion molecule A F11R 4
J3QSB7 Purine nucleoside phosphorylase;S-methyl-5-thioadenosine phosphorylase MTAP 4
Q5VVQ6 Ubiquitin thioesterase OTU1 YOD1 4
P36543 V-type proton ATPase subunit E 1 ATP6V1E1 4
Q9BS40 Latexin LXN 4
P47755 F-actin-capping protein subunit alpha-2 CAPZA2 4
Q9GZT8 NIF3-like protein 1 NIF3L1 4
H6UYS7 Alpha-synuclein SNCA 4
P60953 Cell division control protein 42 homolog CDC42 4
Q14773 Intercellular adhesion molecule 4 ICAM4 4
H0Y6T7 Nicastrin NCSTN 4
P69891 Hemoglobin subunit gamma-1 HBG1 4
P14625 Endoplasmin HSP90B1 4
Q96GD0 Pyridoxal phosphate phosphatase PDXP 4
P08311 Cathepsin G CTSG 4
Q9H9Q2 COP9 signalosome complex subunit 7b COPS7B 4
P09417 Dihydropteridine reductase QDPR 4
F8WE6 Peptidyl-prolyl cis-trans isomerase;Peptidyl-prolyl cis-trans isomerase A PPIA 4
O15173 Membrane-associated progesterone receptor component 2 PGRMC2 4
P28072 Proteasome subunit beta type-6;Proteasome subunit beta type PSMB6 4
H3BSW0 Leucine-rich repeat-containing protein 57 LRRC57 4
Q9UBW8 COP9 signalosome complex subunit 7a COPS7A 4
O00560 Syntenin-1 SDCBP 4
F5H157 Ras-related protein Rab-35 RAB35 4
Q9H479 Fructosamine-3-kinase FN3K 4
Q04917 14-3-3 protein eta YWHAH 4
C9JJ47 AP-2 complex subunit mu AP2M1 4
C9JIG9 Serine/threonine-protein kinase OSR1 OXSR1 4
Q13336 Urea transporter 1 SLC14A1 4
P46926 Glucosamine-6-phosphate isomerase 1;Glucosamine-6-phosphate isomerase;Glucosamine-6-phosphate isomerase 2
GNPDA1;GN
PDA2 4
O43633 Charged multivesicular body protein 2a CHMP2A 4
F8VVB9 Tubulin alpha-1A chain;Tubulin alpha-1C chain;Tubulin alpha-1B chain;Tubulin alpha-3C/D chain;Tubulin alpha-3E chain
TUBA1B;TUB
A1C;TUBA1A
;TUBA3C;TU
BA3E
4
A6PVN5 Serine/threonine-protein phosphatase 2A activator PPP2R4 4
B8ZZB8 CB1 cannabinoid receptor-interacting protein 1 CNRIP1 4
Q9P2R3 Rabankyrin-5 ANKFY1 4
Q86YS7 C2 domain-containing protein 5 C2CD5 4
R4GMR5 26S proteasome non-ATPase regulatory subunit 8 PSMD8 4
E7EM64 COP9 signalosome complex subunit 6 COPS6 4
J3KNI6 Integrin beta;Integrin beta-2 ITGB2 4
H0Y5R6 Uroporphyrinogen decarboxylase UROD 4
M0R165 Epidermal growth factor receptor substrate 15-like 1 EPS15L1 4
O00487 26S proteasome non-ATPase regulatory subunit 14 PSMD14 4
Q13630 GDP-L-fucose synthase TSTA3 4
P55060 Exportin-2 CSE1L 4
P20020 Plasma membrane calcium-transporting ATPase 1;Calcium-transporting ATPase ATP2B1 4
Q9NYU2 UDP-glucose:glycoprotein glucosyltransferase 1 UGGT1 4
H3BND8 Ubiquitin carboxyl-terminal hydrolase;Ubiquitin carboxyl-terminal hydrolase 7 USP7 4
Q9GZP4 PITH domain-containing protein 1 PITHD1 4
D6RD66 WD repeat-containing protein 1 WDR1 4
P48729 Casein kinase I isoform alpha CSNK1A1 4
P25685 DnaJ homolog subfamily B member 1 DNAJB1 4
P14550 Alcohol dehydrogenase [NADP(+)] AKR1A1 4
Q6PCE3 Glucose 1,6-bisphosphate synthase PGM2L1 4
Q9UPN7 Serine/threonine-protein phosphatase 6 regulatory subunit 1 PPP6R1 4
P62805 Histone H4 HIST1H4A 4
P62937 Peptidyl-prolyl cis-trans isomerase A PPIA 4
P30046 D-dopachrome decarboxylase;D-dopachrome decarboxylase-like protein DDT;DDTL 4
Q08495 Dematin DMTN 4
K7EIJ0 WW domain-binding protein 2 WBP2 4
E5RHP7 Carbonic anhydrase 1 CA1 4
P09105 Hemoglobin subunit theta-1 HBQ1 4
E7ESC6 Exportin-7 XPO7 4
P61225 Ras-related protein Rap-2b;Ras-related protein Rap-2c;Ras-related protein Rap-2a RAP2B;RAP2A;RAP2C 4
O15400 Syntaxin-7 STX7 3
Q5VZR0 Golgi-associated plant pathogenesis-related protein 1 GLIPR2 3
P40199 Carcinoembryonic antigen-related cell adhesion molecule 6 CEACAM6 3
P27348 14-3-3 protein theta YWHAQ 3
P62820 Ras-related protein Rab-1A RAB1A 3
C9JEN3 Protein lifeguard 3 TMBIM1 3
Q9UDX3 SEC14-like protein 4 SEC14L4 3
Q9Y570 Protein phosphatase methylesterase 1 PPME1 3
Q96GG9 DCN1-like protein 1;DCN1-like protein DCUN1D1 3
B0YJC4 Vimentin VIM 3
Q86VN1 Vacuolar protein-sorting-associated protein 36 VPS36 3
F8WFB9 Endophilin-B2 SH3GLB2 3
A0A087WVQ
9 Elongation factor 1-alpha 1;Putative elongation factor 1-alpha-like 3
EEF1A1;EEF
1A1P5 3
Q53TN4 Cytochrome b reductase 1 CYBRD1 3
P10809 60 kDa heat shock protein, mitochondrial HSPD1 3
F5H7X1 26S proteasome non-ATPase regulatory subunit 9 PSMD9 3
E9PNW4 CD59 glycoprotein CD59 3
E9PS74 Solute carrier family 43 member 3 SLC43A3 3
P53985 Monocarboxylate transporter 1 SLC16A1 3
Q8WWI5 Choline transporter-like protein 1 SLC44A1 3
E9PIR7 Thioredoxin reductase 1, cytoplasmic TXNRD1 3
Q5TD07 Ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 3
Q9UL25 Ras-related protein Rab-21 RAB21 3
P27824 Calnexin CANX 3
U3KPS2 Myeloblastin PRTN3 3
Q9UKU0 Long-chain-fatty-acid--CoA ligase 6 ACSL6 3
P24666 Low molecular weight phosphotyrosine protein phosphatase ACP1 3
H7C2G2 NAD(P)(+)--arginine ADP-ribosyltransferase;Ecto-ADP-ribosyltransferase 4 ART4 3
I3L1K6 Myosin light chain 4 MYL4 3
Q9UK41 Vacuolar protein sorting-associated protein 28 homolog VPS28 3
Q9NUQ9 Protein FAM49B FAM49B 3
Q9UBQ7 Glyoxylate reductase/hydroxypyruvate reductase GRHPR 3
B8ZZG1 MAGUK p55 subfamily member 6 MPP6 3
Q10567 AP-1 complex subunit beta-1 AP1B1 3
O75387 Large neutral amino acids transporter small subunit 3 SLC43A1 3
Q9BTU6 Phosphatidylinositol 4-kinase type 2-alpha PI4K2A 3
J3KS22 L-xylulose reductase DCXR 3
O15498 Synaptobrevin homolog YKT6 YKT6 3
Q08211 ATP-dependent RNA helicase A DHX9 3
P50416 Carnitine O-palmitoyltransferase 1, liver isoform CPT1A 3
P08237 ATP-dependent 6-phosphofructokinase, muscle type PFKM 3
P14735 Insulin-degrading enzyme IDE 3
Q9H0R3 Transmembrane protein 222 TMEM222 3
Q14166 Tubulin--tyrosine ligase-like protein 12 TTLL12 3
Q14558 Phosphoribosyl pyrophosphate synthase-associated protein 1 PRPSAP1 3
A0A087WTB
8 Ubiquitin carboxyl-terminal hydrolase;Ubiquitin carboxyl-terminal hydrolase isozyme L3 UCHL3 3
Q9NPQ8 Synembryn-A RIC8A 3
F6WQW2 Ran-specific GTPase-activating protein RANBP1 3
Q15691 Microtubule-associated protein RP/EB family member 1 MAPRE1 3
A0A0A0MR5
0 Cullin-4A CUL4A 3
Q96IU4 Alpha/beta hydrolase domain-containing protein 14B ABHD14B 3
Q9P0L0 Vesicle-associated membrane protein-associated protein A VAPA 3
E9PRY8 Elongation factor 1-delta EEF1D 3
Q16543 Hsp90 co-chaperone Cdc37 CDC37 3
P06702 Protein S100-A9 S100A9 3
P13639 Elongation factor 2 EEF2 3
E9PJC7 Tetraspanin;CD82 antigen CD82 3
Q01432 AMP deaminase 3 AMPD3 3
B1AUU8 Epidermal growth factor receptor substrate 15 EPS15 3
P54709 Sodium/potassium-transporting ATPase subunit beta-3 ATP1B3 3
P54727 UV excision repair protein RAD23 homolog B RAD23B 3
P36507 Dual specificity mitogen-activated protein kinase kinase 2 MAP2K2 3
Q9Y2V2 Calcium-regulated heat stable protein 1 CARHSP1 3
P31146 Coronin-1A;Coronin CORO1A 3
Q8IY17 Neuropathy target esterase PNPLA6 3
E7EQR4 Ezrin EZR 3
F8WDS9 LanC-like protein 1 LANCL1 3
X6RJP6 Transgelin-2 TAGLN2 3
A0A0J9YXM
6 WD repeat-containing protein 81 WDR81 3
P62140 Serine/threonine-protein phosphatase PP1-beta catalytic subunit;Serine/threonine-protein phosphatase PPP1CB 3
H0YLJ3 Mortality factor 4-like protein 1 MORF4L1 3
E7EPV7 Alpha-synuclein SNCA 3
K7EK07 Histone H3 H3F3B 3
P05109 Protein S100-A8;Protein S100-A8, N-terminally processed S100A8 3
I3L0A0 Ubiquitin-conjugating enzyme E2 variant 1;Ubiquitin-conjugating enzyme E2 variant 2
TMEM189-
UBE2V1;UBE
2V1;UBE2V2
3
Q6B0K9 Hemoglobin subunit mu HBM 3
O75368 SH3 domain-binding glutamic acid-rich-like protein SH3BGRL 3
A0A0J9YXB3 Ras-related protein Rap-1b;Ras-related protein Rap-1A;Ras-related protein Rap-1b-like protein
RAP1B;RAP1
A 3
P60953 Cell division control protein 42 homolog CDC42 3
A0A087WTI1 Ras-related protein Rab-1B;Ras-related protein Rab-1A RAB1B;RAB1A 3
B5MDF5 GTP-binding nuclear protein Ran RAN 3
P61088 Ubiquitin-conjugating enzyme E2 N UBE2N 3
Q00013 55 kDa erythrocyte membrane protein MPP1 3
B1AKQ8
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1;Guanine nucleotide-binding 
protein G(I)/G(S)/G(T) subunit beta-3;Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-2
GNB1;GNB2;
GNB3 3
P04406 Glyceraldehyde-3-phosphate dehydrogenase GAPDH 3
Q9UJC5 SH3 domain-binding glutamic acid-rich-like protein 2 SH3BGRL2 3
P04921 Glycophorin-C GYPC 2
Q9NP59 Solute carrier family 40 member 1 SLC40A1 2
K7EKH5 Fructose-bisphosphate aldolase;Fructose-bisphosphate aldolase C ALDOC 2
P11233 Ras-related protein Ral-A RALA 2
F8WBR5 Calmodulin CALM2;CALM3;CALM1 2
P00441 Superoxide dismutase [Cu-Zn] SOD1 2
H0YDI1 Lymphocyte function-associated antigen 3 CD58 2
H0YNE9 Ras-related protein Rab-8B RAB8B 2
J3KN67 TPM3 2
P20160 Azurocidin AZU1 2
A0A087WZZ
4 Ammonium transporter Rh type A RHAG 2
F5GXS0 Complement C4-A;Complement C4-B C4B;C4A 2
Q8ND76 Cyclin-Y CCNY 2
Q14739 Lamin-B receptor LBR 2
Q15181 Inorganic pyrophosphatase PPA1 2
J3QS92 Galectin-9 LGALS9 2
I3L471 Phosphatidylinositol transfer protein alpha isoform PITPNA 2
P01111 GTPase NRas NRAS;KRAS 2
F5H4Q5 Vacuolar protein sorting-associated protein 37C VPS37C 2
A0A0A0MSW
4 Phosphatidylinositol transfer protein beta isoform PITPNB 2
P67775 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform;Serine/threonine-protein phosphatase
PPP2CA;PPP
2CB 2
P41091 Eukaryotic translation initiation factor 2 subunit 3;Putative eukaryotic translation initiation factor 2 subunit 3-like protein
EIF2S3;EIF2
S3L 2
A0A087WWS
7 Syntaxin-binding protein 2 STXBP2 2
F8VQX6 Methyltransferase-like protein 7A METTL7A 2
B3KT28 FAS-associated factor 1 FAF1 2
K7EIJ8 Katanin p60 ATPase-containing subunit A-like 2 KATNAL2 2
P20339 Ras-related protein Rab-5A RAB5A 2
O95456 Proteasome assembly chaperone 1 PSMG1 2
K7EK45 Polypyrimidine tract-binding protein 1 PTBP1 2
Q15365 Poly(rC)-binding protein 1;Poly(rC)-binding protein 3 PCBP1;PCBP3 2
Q9BSJ8 Extended synaptotagmin-1 ESYT1 2
H3BP35 Diphosphomevalonate decarboxylase MVD 2
H0Y8C4 Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform PPP2R5D 2
K7EP09 Bifunctional coenzyme A synthase;Phosphopantetheine adenylyltransferase;Dephospho-CoA kinase COASY 2
F8VNT9 Tetraspanin;CD63 antigen CD63 2
Q8NEV1 Casein kinase II subunit alpha 3;Casein kinase II subunit alpha CSNK2A3;CSNK2A1 2
F8VTQ5 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 2
A0A087X2E2 Carcinoembryonic antigen-related cell adhesion molecule 8;Carcinoembryonic antigen-related cell adhesion molecule 1;Carcinoembryonic antigen-related cell adhesion molecule 5
CEACAM8;C
EACAM5;CE
ACAM1
2
H0YAS8 Clusterin;Clusterin beta chain;Clusterin alpha chain;Clusterin CLU 2
E9PP54 Tubulin-specific chaperone cofactor E-like protein TBCEL 2
P43034 Platelet-activating factor acetylhydrolase IB subunit alpha PAFAH1B1 2
Q9NT62 Ubiquitin-like-conjugating enzyme ATG3 ATG3 2
K7ERZ3 Perilipin-3 PLIN3 2
Q6DD88 Atlastin-3 ATL3 2
Q15084-3 Protein disulfide-isomerase A6 PDIA6 2
K7EQH4 ATP synthase subunit alpha, mitochondrial ATP5A1 2
G3V1U5 Vesicle transport protein GOT1B GOLT1B 2
O00186 Syntaxin-binding protein 3 STXBP3 2
Q5T6W2 Heterogeneous nuclear ribonucleoprotein K HNRNPK 2
H0YEY4 ADP-sugar pyrophosphatase NUDT5 2
P35580 Myosin-10 MYH10 2
F5H081 Solute carrier family 2, facilitated glucose transporter member 4 SLC2A4 2
Q9H1C7 Cysteine-rich and transmembrane domain-containing protein 1 CYSTM1 2
K7EJ83 Cyclin-dependent kinase 2;Cyclin-dependent kinase 3 CDK3;CDK2 2
C9J352 Importin subunit alpha-5;Importin subunit alpha-5, N-terminally processed KPNA1 2
H9KV75 Alpha-actinin-1;Alpha-actinin-4;Alpha-actinin-2;Alpha-actinin-3
ACTN1;ACTN
4;ACTN3;AC
TN2
2
A0A0A0MQS
1 Pyrroline-5-carboxylate reductase;Pyrroline-5-carboxylate reductase 3 PYCRL 2
D6RBY0 Rieske domain-containing protein RFESD 2
C9JC71 Low affinity immunoglobulin gamma Fc region receptor III-A FCGR3A 2
P51811 Membrane transport protein XK XK 2
C9J1G2 DnaJ homolog subfamily B member 2 DNAJB2 2
Q9UN37 Vacuolar protein sorting-associated protein 4A;Vacuolar protein sorting-associated protein 4B;Fidgetin-like protein 1
VPS4A;VPS4
B;FIGNL1 2
P61160 Actin-related protein 2 ACTR2 2
P16930 Fumarylacetoacetase FAH 2
A0A087X0K4 CUB and sushi domain-containing protein 2 CSMD2 2
P10746 Uroporphyrinogen-III synthase UROS 2
K7EQ02 DAZ-associated protein 1 DAZAP1 2
F5GYN4 Ubiquitin thioesterase OTUB1 OTUB1 2
P10599 Thioredoxin TXN 2
O95197 Reticulon-3 RTN3 2
E7ETB3 Aspartyl aminopeptidase DNPEP 2
P14868 Aspartate--tRNA ligase, cytoplasmic DARS 2
Q08AM6 Protein VAC14 homolog VAC14 2
Q93034 Cullin-5 CUL5 2
Q9BQA1 Methylosome protein 50 WDR77 2
A0A0B4J2G9 Ubiquitin-conjugating enzyme E2 L3 UBE2L3 2
Q04446 1,4-alpha-glucan-branching enzyme GBE1 2
Q96NA2 Rab-interacting lysosomal protein RILP 2
Q92539 Phosphatidate phosphatase LPIN2 LPIN2 2
P28482 Mitogen-activated protein kinase 1 MAPK1 2
Q7Z406 Myosin-14;Myosin-11 MYH14;MYH11 2
Q8IU68 Transmembrane channel-like protein 8 TMC8 2
Q96BJ3 Axin interactor, dorsalization-associated protein AIDA 2
P20042 Eukaryotic translation initiation factor 2 subunit 2 EIF2S2 2
A0A0A0MQR
0
Docosahexaenoic acid omega-hydroxylase CYP4F3;Phylloquinone omega-hydroxylase 
CYP4F2;Cytochrome P450 4F12;Phylloquinone omega-hydroxylase CYP4F11
CYP4F2;CYP
4F3;CYP4F11
;CYP4F12
2
Q9BS26 Endoplasmic reticulum resident protein 44 ERP44 2
O00178 GTP-binding protein 1 GTPBP1 2
P27797 Calreticulin CALR 2
G3V0E5 Transferrin receptor protein 1;Transferrin receptor protein 1, serum form TFRC 2
P48147 Prolyl endopeptidase PREP 2
H7BZC1 Hippocalcin-like protein 1;Neuron-specific calcium-binding protein hippocalcin;Neurocalcin-delta
HPCAL1;NCA
LD;HPCA 2
F8VPD4 CAD protein;Glutamine-dependent carbamoyl-phosphate synthase;Aspartate carbamoyltransferase;Dihydroorotase CAD 2
Q9NTJ5 Phosphatidylinositide phosphatase SAC1 SACM1L 2
P26447 Protein S100-A4 S100A4 2
Q9UIW2 Plexin-A1 PLXNA1 2
H0YJS0 V-type proton ATPase subunit D ATP6V1D 2
P25445 Tumor necrosis factor receptor superfamily member 6 FAS 2
C9JEU5 Fibrinogen gamma chain FGG 2
F5H562 Copper-transporting ATPase 2;WND/140 kDa ATP7B 2
B5MCF3 Protein GUCD1 GUCD1 2
Q96TA1 Niban-like protein 1 FAM129B 2
F5GWT4 Serine/threonine-protein kinase WNK1 WNK1 2
E9PLT1 Platelet glycoprotein 4 CD36 2
Q8TDB8 Solute carrier family 2, facilitated glucose transporter member 14;Solute carrier family 2, facilitated glucose transporter member 3
SLC2A14;SL
C2A3 2
B4DDD6 Drebrin-like protein DBNL 2
E9PII3 Band 4.1-like protein 2 EPB41L2 2
E9PNF5 Glutamine-dependent NAD(+) synthetase NADSYN1 2
K7ELL7 Glucosidase 2 subunit beta PRKCSH 2
Q9BV20 Methylthioribose-1-phosphate isomerase MRI1 2
J3KNB4 Cathelicidin antimicrobial peptide;Antibacterial protein FALL-39;Antibacterial protein LL-37 CAMP 2
Q5T1Z0 Phospholysine phosphohistidine inorganic pyrophosphate phosphatase LHPP 2
H3BLV0 Complement decay-accelerating factor CD55 2
Q9Y3E7 Charged multivesicular body protein 3 CHMP3 2
Q5T6H7 Xaa-Pro aminopeptidase 1 XPNPEP1 2
O94779 Contactin-5 CNTN5 2
E9PNR2 Ras and Rab interactor 1 RIN1 2
E7ESJ7 Protein FAM114A2 FAM114A2 2
A0A0A0MS9
9 Multidrug resistance-associated protein 1 ABCC1 2
A0A0G2JM1
5 Large neutral amino acids transporter small subunit 4 SLC43A2 2
H0YBF7 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1;Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2
ASAP1;ASAP
2 2
P29992 Guanine nucleotide-binding protein subunit alpha-11 GNA11 2
F8WF69 Clathrin light chain A CLTA 2
B5MCN0 Atlastin-2 ATL2 2
F8W9F9 Serine/threonine-protein kinase WNK2;Serine/threonine-protein kinase WNK3 WNK2;WNK3 2
A2A3F3 Transient receptor potential cation channel subfamily M member 3 TRPM3 2
Q5KU26 Collectin-12 COLEC12 2
O14523 C2 domain-containing protein 2-like C2CD2L 2
Q96DG6 Carboxymethylenebutenolidase homolog CMBL 2
Q5THJ4 Vacuolar protein sorting-associated protein 13D VPS13D 2
Q02790 Peptidyl-prolyl cis-trans isomerase FKBP4;Peptidyl-prolyl cis-trans isomerase FKBP4, N-terminally processed FKBP4 2
A0A0G2JQD Glutathione S-transferase theta-1 GSTT1 2
2Q9NV96 Cell cycle control protein 50A;Cell cycle control protein 50B TMEM30A;TMEM30B 2
P62330 ADP-ribosylation factor 6 ARF6 2
Q9UPU5 Ubiquitin carboxyl-terminal hydrolase 24 USP24 2
B2R4S9 Histone H2B HIST1H2BI 2
P10599 Thioredoxin TXN 2
R4GN98 Protein S100;Protein S100-A6 S100A6 2
H3BS66 Small integral membrane protein 1 SMIM1 2
Q8NHG7 Small VCP/p97-interacting protein SVIP 2
C9JIG9 Serine/threonine-protein kinase OSR1;STE20/SPS1-related proline-alanine-rich protein kinase
OXSR1;STK3
9 2
Q5VZR0 Golgi-associated plant pathogenesis-related protein 1 GLIPR2 2
F8WD49 Anion exchange protein 3;Anion exchange protein;Anion exchange protein 2 SLC4A3;SLC4A2 2
P61626 Lysozyme C;Lysozyme LYZ 2
Q5T123 SH3 domain-binding glutamic acid-rich-like protein 3 SH3BGRL3 2
F5H571 Ubiquitin carboxyl-terminal hydrolase 5 USP5 2
Q9H3K6 BolA-like protein 2 BOLA2;BOLA2B 2
P05164 Myeloperoxidase;Myeloperoxidase;89 kDa myeloperoxidase;84 kDa myeloperoxidase;Myeloperoxidase light chain;Myeloperoxidase heavy chain MPO 2
P50395 Rab GDP dissociation inhibitor beta GDI2 2
G3V2U7 Acylphosphatase;Acylphosphatase-1 ACYP1 2
J3KNB4 Cathelicidin antimicrobial peptide;Antibacterial protein FALL-39;Antibacterial protein LL-37 CAMP 2
H0Y9X3 Programmed cell death protein 6 PDCD6 2
A6NJA2 Ubiquitin carboxyl-terminal hydrolase;Ubiquitin carboxyl-terminal hydrolase 14 USP14 2
P35998 26S protease regulatory subunit 7 PSMC2 2
P30041 Peroxiredoxin-6 PRDX6 2
P35612 Beta-adducin ADD2 2
P00918 Carbonic anhydrase 2 CA2 2
A0A0C4DGH
5 Cullin-associated NEDD8-dissociated protein 1 CAND1 2
C9JZN1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2;Guanine nucleotide-binding protein subunit beta-4 GNB2;GNB4 1
I3L4X8 Integrin beta;Integrin beta-3 ITGB3 1
H7BZJ3 PDIA3 1
P17066 Heat shock 70 kDa protein 6;Putative heat shock 70 kDa protein 7 HSPA6;HSPA7 1
J3KT70 Arf-GAP with dual PH domain-containing protein 2 ADAP2;CENTA2 1
Q9Y6M5 Zinc transporter 1 SLC30A1 1
P54725 UV excision repair protein RAD23 homolog A RAD23A 1
F8WD59 40S ribosomal protein SA RPSA;RPSAP58 1
P06753 1
E9PMI6 Methylosome subunit pICln CLNS1A 1
Q9BVK6 Transmembrane emp24 domain-containing protein 9 TMED9 1
C9JJV6 Myeloid-associated differentiation marker MYADM 1
Q8IXQ3 Uncharacterized protein C9orf40 C9orf40 1
Q8NDC0 MAPK-interacting and spindle-stabilizing protein-like MAPK1IP1L 1
Q99747 Gamma-soluble NSF attachment protein NAPG 1
E7EWE1 Ubiquitin-like modifier-activating enzyme 5 UBA5 1
J3KNE3 Platelet-activating factor acetylhydrolase IB subunit beta PAFAH1B2 1
Q8IUI8 Cytokine receptor-like factor 3 CRLF3 1
Q9BTX7 Alpha-tocopherol transfer protein-like TTPAL 1
P63261 Actin, cytoplasmic 2;Actin, cytoplasmic 2, N-terminally processed ACTG1 1
P31153 S-adenosylmethionine synthase isoform type-2 MAT2A 1
O00560 Syntenin-1 SDCBP 1
Q4VB86 Protein 4.1 EPB41 1
Q8WUD1 Ras-related protein Rab-2B RAB2B;DKFZp313C1541 1
Q9NWV4 UPF0587 protein C1orf123 C1orf123 1
Q9Y2Z0 Suppressor of G2 allele of SKP1 homolog SUGT1 1
H0YK48 Tropomyosin alpha-1 chain TPM1 1
H3BS66 Small integral membrane protein 1 SMIM1 1
Q5VTS0 Neurensin-1 NRSN1 1
H0Y904 Multidrug resistance-associated protein 7 ABCC10 1
P08F94 Fibrocystin PKHD1 1
G3V5X4 Nesprin-2 SYNE2 1
P48507 Glutamate--cysteine ligase regulatory subunit GCLM 1
H3BUF4 Cyclin-D1-binding protein 1 CCNDBP1 1
F8WB30 Target of Myb protein 1 TOM1 1
E5RJI8 CA1 1
S4R3E5 Importin subunit alpha-7 KPNA6 1
E7EVS6 ACTB 1
P04206 Ig kappa chain V-III region GOL;Ig kappa chain V-III region WOL;Ig kappa chain V-III region Ti;Ig kappa chain V-III region SIE 1
Q5SSV3 N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 DDAH2 1
H0YG54 Oligoribonuclease, mitochondrial REXO2 1
P08246 Neutrophil elastase ELANE 1
P40926 Malate dehydrogenase, mitochondrial MDH2 1
P98172 Ephrin-B1 EFNB1 1
Q96DD7 Protein shisa-4 SHISA4 1
Q71RC9 Small integral membrane protein 5 SMIM5 1
P68133 Actin, alpha skeletal muscle;Actin, alpha cardiac muscle 1;Actin, gamma-enteric smooth muscle;Actin, aortic smooth muscle
ACTA1;ACTC
1;ACTG2;AC
TA2
1
H0Y9Q6 Clathrin light chain B CLTB 1
G3V5P0 KTN1 1
Q9NWX6 Probable tRNA(His) guanylyltransferase THG1L 1
Q15404 Ras suppressor protein 1 RSU1 1
B2R4S9 Histone H2B HIST1H2B 1
K7EK06 Phenylalanine--tRNA ligase alpha subunit FARSA 1
H7C3S9 COP9 signalosome complex subunit 8 COPS8 1
J3KRV4 Dual specificity mitogen-activated protein kinase kinase 3 MAP2K3 1
Q15042 Rab3 GTPase-activating protein catalytic subunit RAB3GAP1 1
P01893
Putative HLA class I histocompatibility antigen, alpha chain H;HLA class I histocompatibility 
antigen, Cw-6 alpha chain;HLA class I histocompatibility antigen, B-38 alpha chain;HLA class 
I histocompatibility antigen, B-67 alpha chain;HLA class I histocompatibility antigen, B-82 
alpha chain;HLA class I histocompatibility antigen, B-39 alpha chain;HLA class I 
HLA-H;HLA-
C;HLA-B 1
histocompatibility antigen, Cw-18 alpha chain;HLA class I histocompatibility antigen, Cw-7 
alpha chain;HLA class I histocompatibility antigen, B-42 alpha chain;HLA class I 
histocompatibility antigen, B-14 alpha chain;HLA class I histocompatibility antigen, B-8 alpha 
chain;HLA class I histocompatibility antigen, B-7 alpha chain
Q9UNW1 Multiple inositol polyphosphate phosphatase 1 MINPP1 1
Q6B0K9 Hemoglobin subunit mu HBM 1
O75915 PRA1 family protein 3 ARL6IP5 1
O95376 E3 ubiquitin-protein ligase ARIH2 ARIH2 1
E9PBW4 Hemoglobin subunit gamma-2 HBG2 1
C9J1X0 WD repeat-containing protein 91 WDR91 1
Q8NCV1 1
Q9Y4P8 WD repeat domain phosphoinositide-interacting protein 2 WIPI2 1
A0A087WUX
6 Proteasomal ubiquitin receptor ADRM1 ADRM1 1
Q9NQS7 Inner centromere protein INCENP 1
P62805 Histone H4 HIST1H4A 1
Q8TDY2 RB1-inducible coiled-coil protein 1 RB1CC1 1
C9JFM5 Syntaxin-4 STX4 1
B0QZ43 Erlin-2;Erlin-1 ERLIN1;ERLIN2 1
C9J8T0 Selenocysteine-specific elongation factor EEFSEC 1
P61224 Ras-related protein Rap-1b;Ras-related protein Rap-1b-like protein RAP1B 1
Q99828 Calcium and integrin-binding protein 1 CIB1 1
Q53GQ0 Very-long-chain 3-oxoacyl-CoA reductase HSD17B12 1
H0Y9Q9 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 BST1 1
R4GN98 Protein S100;Protein S100-A6 S100A6 1
Q8TB73 Protein NDNF NDNF 1
Q6P1A2 Lysophospholipid acyltransferase 5 LPCAT3 1
F2Z2Y4 Pyridoxal kinase PDXK 1
Q9HA65 TBC1 domain family member 17 TBC1D17 1
G3V126 V-type proton ATPase subunit H ATP6V1H 1
D6RGE2 Isochorismatase domain-containing protein 1 ISOC1 1
A0A0B4J222 ADP-ribosylation factor-like protein 15 ARL15 1
F8W7W4 Androglobin ADGB 1
Q9GZR7 1
A0A087WVC
4 cAMP-dependent protein kinase catalytic subunit beta PRKACB 1
A8MU39 Serine/threonine-protein phosphatase;Serine/threonine-protein phosphatase 5 PPP5C 1
G3V1N2 HBA2 1
P69892 Hemoglobin subunit gamma-2 HBG2 1
F8WEZ0 1-phosphatidylinositol 3-phosphate 5-kinase PIKFYVE 1
A0A087WZZ
4 Ammonium transporter Rh type A RHAG 1
Q1JUQ3 Peptidyl-prolyl cis-trans isomerase;Peptidyl-prolyl cis-trans isomerase FKBP1A FKBP12-Exin;FKBP1A 1
F8VWZ5 H2.0-like homeobox protein HLX 1
P62877 E3 ubiquitin-protein ligase RBX1;E3 ubiquitin-protein ligase RBX1, N-terminally processed RBX1 1
Q7Z5P9 Mucin-19 MUC19 1
F8VPB3 TPK1 1
F8WBF4 Transmembrane protein 50B TMEM50B 1
C9JL85 Myotrophin MTPN 1
Q53EQ6 Tigger transposable element-derived protein 5 TIGD5 1
E3W974 DNPEP 1
H7BYV1 Interferon-induced transmembrane protein 1;Interferon-induced transmembrane protein 2;Interferon-induced transmembrane protein 3
IFITM2;IFITM
3;IFITM1 1
D6RC06 Histidine triad nucleotide-binding protein 1 HINT1 1
E9PNW4 CD59 glycoprotein CD59 1
H7C2Z6 Grancalcin GCA 1
Q9H1C7 Cysteine-rich and transmembrane domain-containing protein 1 CYSTM1 1
H0YK07 ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial CLPX 1
E9PG15 14-3-3 protein theta YWHAQ 1
K7ENK9 Vesicle-associated membrane protein 3;Vesicle-associated membrane protein 2 VAMP2;VAMP3 1
F8WDD6 Cation channel sperm-associated protein subunit gamma CATSPERG 1
P35754 Glutaredoxin-1 GLRX 1
Q5THJ4 Vacuolar protein sorting-associated protein 13D VPS13D 1
B4E3H6 Transforming acidic coiled-coil-containing protein 1 TACC1 1
B0YJC4 Vimentin VIM 1
H7C5R6 AT-rich interactive domain-containing protein 4B ARID4B 1
P49755 Transmembrane emp24 domain-containing protein 10 TMED10 1
E9PMJ3 Ribonuclease inhibitor RNH1 1
B1AHA9 DNA replication licensing factor MCM5 MCM5 1
P23634 Plasma membrane calcium-transporting ATPase 4 ATP2B4 1
Q14152 Eukaryotic translation initiation factor 3 subunit A EIF3A 1
C9IY70 60S ribosomal export protein NMD3 NMD3 1
A0A087WUS
7 Ig delta chain C region IGHD 1
P07384 Calpain-1 catalytic subunit CAPN1 1
G3V2C9 Guanine nucleotide-binding protein subunit gamma;Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 GNG2 1
Q9Y2Y8 Proteoglycan 3 PRG3 1
V9GY70 DNAJB12 1
U5GXS0 MAM and LDL-receptor class A domain-containing protein 1 MALRD1 1
Q92625 Ankyrin repeat and SAM domain-containing protein 1A ANKS1A 1
Table S3. Complete list of proteins identified in the EEV proteome. Lists of the protein groups identified by 
LC-MS/MS analysis using Andromeda/MaxQuant search engine in the Uniprot Complete Proteome Homo 
sapiens database for the non-depleted sample (356 proteins) (A) or when hemoglobin was analyzed 
separately (818 proteins) (B). The lists were filtered at 1% False Discovery Rate using a target/decoy 
database search.
